2-hydroxycycloalkane-1-carbamoyl derivatives

ABSTRACT

The present invention relates to compounds of Formula (I) 
     
       
         
         
             
             
         
       
     
     wherein Ar 1 , Ar 2 , L, n, and R 1  are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

The present invention relates to compounds of formula (I) which aregalectin-3 inhibitors and their use in the prevention/prophylaxis ortreatment of diseases and disorders that are related to galectin-3binding to natural ligands. The invention also concerns related aspectsincluding processes for the preparation of the compounds, pharmaceuticalcompositions containing one or more compounds of formula (I), and theirmedical use as Galectin-3 inhibitors. The compounds of formula (I)) mayespecially be used as single agents or in combination with one or moretherapeutic agents.

Galectins are defined as a protein family based on conservedβ-galactoside-binding sites found within their characteristic ˜130 aminoacid (aa) carbohydrate recognition domains (CRDs) (Barondes S H et al.,Cell 1994; 76, 597-598). Human, mouse and rat genome sequences revealthe existence of at least 16 conserved galectins and galectin-likeproteins in one mammalian genome (Leffler H. et al., Glycoconj. J. 2002,19, 433-440). So far, three galectin subclasses were identified, theprototypical galectins containing one carbohydrate-recognition domain(CRD); the chimaera galectin consisting of unusual tandem repeats ofproline- and glycine-rich short stretches fused onto the CRD; and thetandem-repeat-type galectins, containing two distinct CRDs in tandemconnected by a linker (Zhong X., Clin Exp Pharmacol Physiol. 2019;46:197-203). As galectins can bind either bivalently or multivalently,they can e.g. cross-link cell surface glycoconjugates to triggercellular signaling events. Through this mechanism, galectins modulate awide variety of biological processes (Sundblad V. et al., HistolHistopathol 2011; 26: 247-265).

Galectin-3 (Gal-3), the only chimaera type in the galectin family, has amolecular weight of 32-35 kDa and consists of 250 amino acid residues inhumans, a highly conserved CRD and an atypical N-terminal domain (ND).Galectin-3 is monomeric up to high concentrations (100 μM), but canaggregate with ligands at much lower concentrations, which is promotedby its N-terminal non-CRD region via an oligomerisation mechanism thatis not yet completely understood (Johannes, L. et al., Journal of CellScience 2018; 131, jcs208884).

Gal-3 is widely distributed in the body, but the expression level variesamong different organs. Depending on its extracellular or intracellularlocalization, it can display a broad diversity of biological functions,including immunomodulation, host-pathogen interactions, angiogenesis,cell migration, wound healing and apoptosis (Sundblad V. et al., HistolHistopathol 2011; 26: 247-265). Gal-3 is highly expressed in many humantumours and cell types, such as myeloid cells, inflammatory cells(macrophages, mast cells, neutrophils, T cells, eosinophils, etc.),fibroblasts and cardiomyocytes (Zhong X. et al., Clin Exp PharmacolPhysiol. 2019; 46:197-203), indicating that Gal-3 is involved in theregulation of inflammatory and fibrotic processes (Henderson N C. Etal., Immunological Reviews 2009; 230: 160-171; Sano H. et al., JImmunol. 2000; 165(4):2156-64). Furthermore, Gal-3 protein expressionlevels are up-regulated under certain pathological conditions, such asneoplasms and inflammation (Chiariotti L. et al., Glycoconjugate Journal2004 19, 441-449; Farhad M. et al., OncoImmunology 2018, 7:6, e1434467).

There are multiple lines of evidence supporting functional involvementof Gal-3 in the development of inflammatory/autoimmune diseases, such asasthma (Gao P. et al. Respir Res. 2013, 14:136; Rao S P et al. Front Med(Lausanne) 2017; 4:68), rheumatoid arthritis, multiple sclerosis,diabetes, plaque psoriasis (Lacina L. et al. Folia Biol (Praha) 2006;52(1-2):10-5) atopic dermatitis (Saegusa J. et al. Am J Pathol. 2009,174(3):922-31), endometriosis (Noel J C et al. Appl Immunohistochem MolMorphol. 2011 19(3):253-7), or viral encephalitis (Liu F T et al., Ann NY Acad Sci. 2012; 1253:80-91; Henderson N C, et al., Immunol Rev. 2009;230(1):160-71; Li P et al., Cell 2016; 167:973-984). Recently Gal-3 hasemerged as a key player of chronic inflammation and organ fibrogenesisdevelopment e.g. liver (Henderson N C et al., PNAS 2006; 103: 5060-5065;Hsu D K et al. Int J Cancer. 1999, 81(4):519-26), kidney (Henderson N Cet al., Am. J. Pathol. 2008; 172:288-298; Dang Z. et al.Transplantation. 2012, 93(5):477-84), lung (Mackinnon A C et al., Am. J.Respir. Crit. Care Med 2012, 185: 537-546; Nishi Y. et al. Allergol Int.2007, 56(1):57-65), heart (Thandavarayan R A et al. Biochem Pharmacol.2008, 75(9):1797-806; Sharma U. et al. Am J Physiol Heart Circ Physiol.2008; 294(3):H1226-32), as well as the nervous system (Burguillos M A etal. Cell Rep. 2015, 10(9):1626-1638), and in corneal neovascularization(Chen W S. Et al., Investigative Ophthalmology & Visual Science 2017,Vol. 58, 9-20). Additionally, Gal-3 was found to be associated withdermal thickening of keold tissues (Arciniegas E. et al., The AmericanJoumal of dermatopathology 2019; 41(3):193-204) and systemic sclerosis(SSc) especially with skin fibrosis and proliferative vasculopathyobserved in such condition (Taniguchi T. et al. J Rheumatol. 2012,39(3):539-44). Gal-3 was found to be up-regulated in patient sufferingchronic kidney disease (CKD) associated-kidney failure, and especiallyin those affected by diabetes. Interestingly, data obtained from thispatient population showed correlation between Gal-3 upregulation inglomeruli and the observed urinary protein excretion (Kikuchi Y. et al.Nephrol Dial Transplant. 2004, 19(3):602-7). Additionally, a recentprospective study from 2018 demonstrated that higher Gal-3 plasma levelsare associated with an elevated risk of developing incident CKD,particularly among hypertension-suffering population (Rebholz C M. etal. Kidney Int. 2018 January; 93(1): 252-259). Gal-3 is highly elevatedin cardiovascular diseases (Zhong X. et al. Clin Exp Pharmacol Physiol.2019, 46(3):197-203), such as atherosclerosis (Nachtigal M. et al. Am JPathol. 1998; 152(5):1199-208), coronary artery disease (Falcone C. etal. Int J Immunopathol Pharmacol 2011, 24(4):905-13), heart failure andthrombosis (Nachtigal M. et al., Am J Pathol. 1998; 152(5):1199-208;Gehlken C. et al., Heart Fail Clin. 2018, 14(1):75-92; DeRoo E P. etal., Blood. 2015, 125(11):1813-21). Gal-3 blood concentration iselevated in obese and diabetic patients and is associated with a higherrisk for micro- and macro-vascular complication (such as heart failure,nephropathy/retinopathy, peripheral arterial disease, cerebrovascularevent, or myocardial infarction) (Qi-hui-Jin et al. Chin Med J (Engl).2013, 126(11):2109-15). Gal-3 influences oncogenesis, cancerprogression, and metastasis (Vuong L. et al., Cancer Res 2019 (79) (7)1480-1492), and was shown to exert a role as a pro-tumor factor byacting within the micro tumor environment to suppress immunesurveillance (Ruvolo P P. et al. Biochim Biophys Acta. 2016 March,1863(3):427-437; Farhad M. et al. Oncoimmunology 2018 Feb. 20;7(6):e1434467). Among the cancers that express high level of Gal-3 arefound those affecting the thyroid gland, the central nervous system, thetongue, the breast, the gastric cancer, the head and neck squamous cell,the pancreas, the bladder, the kidney, the liver, the parathyroid, thesalivary glands, but also lymphoma, carcinoma, non-small cell lungcancer, melanoma and neuroblastoma (Sciacchitano S. et al. Int J Mol Sci2018 Jan. 26, 19(2):379).

Also, Gal-3 inhibition has been proposed to be beneficial in thetreatment of COVD-19 (Caniglia J L et al. PeerJ 2020, 8:e9392) andinfluenza H5N1 (Chen Y J et al. Am. J. Pathol. 2018, 188(4), 1031-1042)possibly due to anti-inflammatory effects.

Recently, Gal-3 inhibitors have shown to have positive effects when usedin combination immunotherapy (Galectin Therapeutics. Press Release, Feb.7, 2017) and idiopathic pulmonary fibrosis (Galecto Biotech. PressRelease, Mar. 10, 2017) and in NASH cirrhosis (Dec. 5, 2017).WO20180209276, WO2018209255 and WO20190890080 disclose compounds havingbinding affinity with galectin proteins for the treatment of systemicinsulin resistance disorders. Thus, Gal-3 inhibitors, alone or incombination with other therapies, may be useful for the prevention ortreatment of diseases or disorders such as fibrosis of organs,cardiovascular diseases and disorders, acute kidney injury and chronickidney disease, liver diseases and disorders, interstitial lung diseasesand disorders, ocular diseases and disorders, cell proliferativediseases and cancers, inflammatory and autoimmune diseases anddisorders, gastrointestinal tract diseases and disorders, pancreaticdiseases and disorders, abnormal angiogenesis-associated diseases anddisorders, brain-associated diseases and disorders, neuropathic pain andperipheral neuropathy, and/or transplant rejection.

Several publications and patent applications describe syntheticinhibitors of Gal-3 that are being explored as antifibrotic agents (seefor example WO2005113568, WO2005113569, WO2014067986, WO2016120403,US20140099319, WO2019067702, WO2019075045, WO2014078655, WO2020078807and WO2020078808).

The present invention provides novel compounds of formula (I) which areGalectin-3 inhibitors. The present compounds may, thus, be useful forthe prevention/prophylaxis or treatment of diseases and disorders wheremodulation of Gal-3 binding to its natural carbohydrate ligands isindicated.

1) In a first embodiment, the invention relates to a compound of theFormula (I),

whereinn represents the integer 1 or 2 (especially n is 1);Ar¹ represents

-   -   aryl (especially phenyl) which is mono-, di-, tri-, tetra-, or        penta-substituted (especially mono-, di-, or tri-substituted),        wherein the substituents are independently selected from        halogen; methyl; cyano; methoxy; trifluoromethyl;        trifluoromethoxy; NR^(N11)R^(N12) wherein R^(N11) represents        hydrogen and R^(N12) represents hydroxy-C₂₋₃-alkyl (especially        3-hydroxy-propl-yl), or R^(N11) and R^(N12) together with the        nitrogen atom to which they are attached form a 4- to 6-membered        heterocyclyl selected from morpholin-4-yl, azetidine-1-yl,        pyrrolidine-1-yl, and piperidine-1-yl (especially        morpholin-4-yl), wherein said 4- to 6-membered heterocyclyl is        unsubstituted or mono-substituted with hydroxy (notably selected        from halogen, methyl, cyano, and methoxy);    -   [wherein in particular at least one of said substituents is        attached in a meta-, or in para-position of said phenyl;        wherein, if present, such substituent in para-position is        preferably selected from halogen, methyl, cyano, and methoxy;        and, if present, such substituent in meta-position is preferably        halogen];    -   5- or 6-membered heteroaryl (especially thiazolyl), wherein said        5- or 6-membered heteroaryl independently is unsubstituted,        mono- or di-substituted, wherein the substituents are        independently selected from halogen, methyl, cyano, and methoxy;        or    -   9- or 10-membered heteroaryl (especially benzothiazolyl),        wherein said 9- or 10-membered heteroaryl independently is        unsubstituted, or mono-substituted with methyl;        R¹ represents    -   hydroxy;    -   C₁₋₃-alkoxy (especially methoxy);    -   —O—CO—C₁₋₃-alkyl;    -   —O—CH₂—CH₂—OH; or    -   —O—CH₂CO—R^(1X) wherein R^(1X) represents        -   -hydroxy;        -   morpholin-4-yl; or        -   —NR^(N21)R^(N22), wherein R^(N21) and R^(N22) together with            the nitrogen atom to which they are attached form a 4- to            6-membered heterocyclyl selected from azetidine-1-yl,            pyrrolidine-1-yl, and piperidine-1-yl, wherein said 4- to            6-membered heterocyclyl is mono-substituted with hydroxy;    -   L represents a direct bond, methylene, or ethylene (especially a        direct bond or methylene); and    -   Ar² represents        -   phenyl or 5- or 6-membered heteroaryl (especially furanyl,            thiophenyl, pyrrolyl, thiazoyl, isothiazolyl, isoxazolyl,            pyrazolyl, imidazolyl, pyridinyl, or pyrimidinyl), wherein            said phenyl or 5- or 6-membered heteroaryl independently is            unsubstituted, or mono-, di- or tri-substituted (notably            mono-, or di-substituted) wherein the substituents            independently are selected from C₁₋₆-alkyl, C₃₋₆-cycloalkyl,            —CH₂—C₃₋₆-cycloalkyl, C₁₋₃-fluoroalkyl, C₁₋₃-fluoroalkoxy,            C₁₋₃-alkoxy, halogen, morpholine-4-yl, amino, ethynyl and            cyano;        -   9-membered bicyclic heteroaryl (especially indolyl, or            benzothiophenyl, benzothiazolyl, or benzoimidazolyl) or            10-membered bicyclic heteroaryl (especially quinolinyl or            quinoxalinyl), wherein said 9- or 10-membered bicyclic            heteroaryl independently is unsubstituted, mono- or            di-substituted, wherein the substituents independently are            selected from methyl, methoxy, and halogen (especially            fluoro, chloro); or        -   naphthyl.

The compounds of Formula (I) contain five stereogenic or asymmetriccenters, which are situated on the tetrahydropyran moiety, and twostereogenic or asymmetric centers situated on the cycloalkane moietywhich are in the absolute (S,S)-configuration as drawn for Formula (I).In addition, the compounds of Formula (I) may contain one, and possiblymore stereogenic or asymmetric centers, such as one or more additionalasymmetric carbon atoms. The compounds of Formula (I) may thus bepresent as mixtures of stereoisomers or preferably as purestereoisomers. Mixtures of stereoisomers may be separated in a mannerknown to a person skilled in the art.

In case a particular compound (or generic structure) is designated asbeing in a certain absolute configuration, e.g. as (R)- or(S)-enantiomer, such designation is to be understood as referring to therespective compound (or generic structure) in enriched, especiallyessentially pure, enantiomeric form. Likewise, in case a specificasymmetric center in a compound is designated as being in (R)- or(S)-configuration or as being in a certain relative configuration, suchdesignation is to be understood as referring to the compound that is inenriched, especially essentially pure, form with regard to therespective configuration of said asymmetric center. In analogy, twostereogenic centers e.g in a cyclic group may be present in a certainrelative configuration. Accordingly, cis- or trans-designations (or(R*,R*) designations as used e.g. for certain intermediates of thepresent compounds) are to be understood as referring to the respectivestereoisomer of the respective relative configuration in enriched form,especially in essentially pure form. Thus, for a given molecule orgroup, the designation (R*,R*), if not explicitly specified otherwise,includes the respective (R,R)-enantiomer, the (S,S)-enantiomer, and anymixture of these two enantiomers including the racemate.

The term “enriched”, when used in the context of stereoisomers, is to beunderstood in the context of the present invention to mean that therespective stereoisomer is present in a ratio of at least 70:30,especially of at least 90:10 (i.e., in a purity of at least 70% byweight, especially of at least 90% by weight), with regard to therespective other stereoisomer/the entirety of the respective otherstereoisomers.

The term “essentially pure”, when used in the context of stereoisomers,is to be understood in the context of the present invention to mean thatthe respective stereoisomer is present in a purity of at least 95% byweight, especially of at least 99% by weight, with regard to therespective other stereoisomer/the entirety of the respective otherstereoisomers.

The present invention also includes isotopically labelled, especially ²H(deuterium) labelled compounds of Formula (I) according toembodiments 1) to 20), which compounds are identical to the compounds ofFormula (I) except that one or more atoms have each been replaced by anatom having the same atomic number but an atomic mass different from theatomic mass usually found in nature. Isotopically labelled, especially²H (deuterium) labelled compounds of formulae (I), (II) and (III) andsalts thereof are within the scope of the present invention.Substitution of hydrogen with the heavier isotope ²H (deuterium) maylead to greater metabolic stability, resulting e.g. in increased in-vivohalf-life or reduced dosage requirements, or may lead to reducedinhibition of cytochrome P450 enzymes, resulting e.g. in an improvedsafety profile. In one embodiment of the invention, the compounds ofFormula (I) are not isotopically labelled, or they are labelled onlywith one or more deuterium atoms. In a sub-embodiment, the compounds ofFormula (I) are not isotopically labelled at all. Isotopically labelledcompounds of Formula (I) may be prepared in analogy to the methodsdescribed hereinafter, but using the appropriate isotopic variation ofsuitable reagents or starting materials.

In this patent application, a bond drawn as a dotted line shows thepoint of attachment of the radical drawn. For example, the radical drawnbelow

is a 3-fluorophenyl group.

Where the plural form is used for compounds, salts, pharmaceuticalcompositions, diseases and the like, this is intended to mean also asingle compound, salt, or the like.

Any reference to compounds of Formula (I) according to embodiments 1) to20) is to be understood as referring also to the salts (and especiallythe pharmaceutically acceptable salts) of such compounds, as appropriateand expedient.

The term “pharmaceutically acceptable salts” refers to salts that retainthe desired biological activity of the subject compound and exhibitminimal undesired toxicological effects. Such salts include inorganic ororganic acid and/or base addition salts depending on the presence ofbasic and/or acidic groups in the subject compound. For reference seefor example “Handbook of Pharmaceutical Salts. Properties, Selection andUse.”, P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008;and “Pharmaceutical Salts and Co-crystals”, Johan Wouters and Luc Quéré(Eds.), RSC Publishing, 2012.

Definitions provided herein are intended to apply uniformly to thecompounds of Formula (I), as defined in any one of embodiments 1) to18), and, mutatis mutandis, throughout the description and the claimsunless an otherwise expressly set out definition provides a broader ornarrower definition. It is well understood that a definition orpreferred definition of a term defines and may replace the respectiveterm independently of (and in combination with) any definition orpreferred definition of any or all other terms as defined herein.

In this patent application, the compounds are named using IUPACnomenclature, but can also be named using carbohydrate nomenclature.Thus, the moiety:

can be named(2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carbonylor, alternatively,1,3-di-deoxy-3-[4-phenyl-1H-1,2,3-triazol-1-yl]-β-D-galactopyranoside-1-carbonyl,wherein the absolute configuration of carbon atom carrying the carbonylgroup which is the point of attachment to the rest of the molecule is in(2R)—, respectively, beta-configuration. For example, compound(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-pyrrol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamideis to be understood as also referring to:1,3-di-deoxy-2-O-methyl-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-((1-methyl-1H-pyrrol-2-yl)methyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide.

Whenever a substituent is denoted as optional, it is understood thatsuch substituent may be absent (i.e. the respective residue isunsubstituted with regard to such optional substituent), in which caseall positions having a free valency (to which such optional substituentcould have been attached to; such as for example in an aromatic ring thering carbon atoms and/or the ring nitrogen atoms having a free valency)are substituted with hydrogen where appropriate. Likewise, in case theterm “optionally” is used in the context of (ring) heteroatom(s), theterm means that either the respective optional heteroatom(s), or thelike, are absent (i.e. a certain moiety does not containheteroatom(s)/is a carbocycle/or the like), or the respective optionalheteroatom(s), or the like, are present as explicitly defined. If notexplicitly defined otherwise in the respective embodiment or claim,groups defined herein are unsubstituted.

The term “halogen” means fluorine, chlorine, or bromine, preferablyfluorine or chlorine.

The term “alkyl”, used alone or in combination, refers to a saturatedstraight or branched chain hydrocarbon group containing one to sixcarbon atoms. The term “C_(x-y)-alkyl” (x and y each being an integer),refers to an alkyl group as defined before, containing x to y carbonatoms. For example, a C₁₋₆-alkyl group contains from one to six carbonatoms. Representative examples of alkyl groups are methyl, ethyl,propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, 3-methyl-butyl,2,2-dimethyl-propyl and 3,3-dimethyl-butyl. Preferred is methyl. Foravoidance of any doubt, in case a group is referred to as e.g. propyl orbutyl, it is meant to be n-propyl, respectively n-butyl. In case thesubstituent of Ar² (being phenyl or 5- or 6-membered heteroaryl)represents “C₁₋₆-alkyl”, the term especially refers to methyl, ethyl, orisopropyl; in particular to methyl.

The term “—C_(x-y)-alkylene-”, used alone or in combination, refers tobivalently bound alkyl group as defined before containing x to y carbonatoms. The term “—C_(0-y)-alkylene-” refers to a direct bond, or to a—(C_(1-y))alkylene- as defined before. Preferably, the points ofattachment of a —C_(1-y)-alkylene group are in 1,1-diyl, or in 1,2-diyl,or in 1,3-diyl arrangement. Preferably, the points of attachment of a—C_(2-y)-alkylene group are in 1,2-diyl or in 1,3-diyl arrangement. Incase a C_(0 y)-alkylene group is used in combination with anothersubstituent, the term means that either said substituent is linkedthrough a C_(1 y)-alkylene group to the rest of the molecule, or it isdirectly attached to the rest of the molecule (i.e. a Co-alkylene grouprepresents a direct bond linking said substituent to the rest of themolecule). The alkylene group —C₂H₄— (or ethylene) refers to —H₂—CH₂— ifnot explicitly indicated otherwise.

The term “alkenyl”, used alone or in combination, refers to a straightor branched hydrocarbon chain containing two to five carbon atoms andone carbon-carbon double bond. The term “C_(x-y)-alkenyl” (x and y eachbeing an integer), refers to an alkenyl group as defined beforecontaining x to y carbon atoms. For example, a C₂₋₅-alkenyl groupcontains from two to five carbon atoms.

The term “fluoroalkyl”, used alone or in combination, refers to an alkylgroup as defined before containing one to three carbon atoms in whichone or more (and possibly all) hydrogen atoms have been replaced withfluorine. The term “C_(x-y)-fluoroalkyl” (x and y each being an integer)refers to a fluoroalkyl group as defined before containing x to y carbonatoms. For example, a C₁₋₃-fluoroalkyl group contains from one to threecarbon atoms in which one to seven hydrogen atoms have been replacedwith fluorine. Representative examples of fluoroalkyl groups includetrifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl and2,2,2-trifluoroethyl. Preferred is trifluoromethyl.

The term ‘fluoroalkoxy’, used alone or in combination, refers to analkoxy group as defined before containing one to three carbon atoms inwhich one or more (and possibly all) hydrogen atoms have been replacedwith fluorine. The term “C_(x-y)-fluoroalkoxy” (x and y each being aninteger) refers to a fluoroalkoxy group as defined before containing xto y carbon atoms. For example, a C₁₋₃-fluoroalkoxy group contains fromone to three carbon atoms in which one to seven hydrogen atoms have beenreplaced with fluorine. Representative examples of fluoroalkoxy groupsinclude trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy,2,2-difluoroethoxy and 2,2,2-trifluoroethoxy.

The term “cycloalkyl”, used alone or in combination, refers especiallyto a saturated monocyclic, or to a fused-, bridged-, or spiro-bicyclichydrocarbon ring containing three to eight carbon atoms. The term“C_(x-y)-cycloalkyl” (x and y each being an integer), refers to acycloalkyl group as defined before containing x to y carbon atoms. Forexample, a C₃₋₆-cycloalkyl group contains from three to six carbonatoms. Examples of cycloalkyl groups are cyclopropyl, cyclobutyl,cyclopentyl, and cyclohexyl. Preferred is cyclopropyl.

The term “alkoxy”, used alone or in combination, refers to an alkyl-O—group wherein the alkyl group is as defined before. The term“C_(x-y)-alkoxy” (x and y each being an integer) refers to an alkoxygroup as defined before containing x to y carbon atoms. Preferred areethoxy and especially methoxy. In case R¹ represents “C₁₋₃-alkoxy” theterm especially refers to methoxy. In case the substituent of Ar² (beingphenyl or 5- or 6-membered heteroaryl) represents “C₁₋₃-alkoxy”, theterm especially refers to methoxy.

The term “heterocyclyl”, used alone or in combination, and if notexplicitly defined in a broader or more narrow way, refers to asaturated or unsaturated non-aromatic monocyclic hydrocarbon ringcontaining one or two ring heteroatoms independently selected fromnitrogen, sulfur, and oxygen (especially one oxygen atom, one sulfuratom, one nitrogen atom, two nitrogen atoms, two oxygen atoms, onenitrogen atom and one oxygen atom). The term “C_(x-y)-heterocycyl”refers to such a heterocycle containing x to y ring atoms. Heterocyclylgroups are unsubstituted or substituted as explicitly defined.

The term “aryl”, used alone or in combination, means phenyl or naphthyl,preferably phenyl, wherein said aryl group is unsubstituted orsubstituted as explicitly defined.

The term “heteroaryl”, used alone or in combination, and if notexplicitly defined in a broader or more narrow way, means a 5- to10-membered monocyclic or bicyclic aromatic ring containing one to amaximum of four heteroatoms, each independently selected from oxygen,nitrogen and sulfur. Representative examples of such heteroaryl groupsare 5-membered heteroaryl groups such as furanyl, oxazolyl, isoxazolyl,oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl,pyrrolyl, imidazolyl, pyrazoyl, triazolyl, tetriazolyl; 6-memberedheteroaryl groups such as pyridinyl, pyrimidinyl, pyridazinyl,pyrazinyl; and 8- to 10-membered bicyclic heteroaryl groups such asindolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl,indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl,benzoisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl,thienopyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl,quinazolinyl, quinoxalinyl, phthalazinyl, pyrrolopyridinyl,pyrazolopyridinyl, pyrazolopyrimidinyl, pyrrolopyrazinyl,imidazopyridinyl, imidazopyridazinyl, and imidazothiazolyl. Theabove-mentioned heteroaryl groups are unsubstituted or substituted asexplicitly defined. For the substituent Ar² representing “5- or6-membered heteroaryl”, the term especially means furanyl, thiophenyl,pyrrolyl, thiazolyl, isothiazolyl, isoxazolyl, pyrazolyl, imidazolyl,pyridinyl, or pyrimidinyl; notably furan-2-yl, thiophen-2-yl,thiophen-3-yl, 1H-pyrrol-2-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl,isothiazol-4-yl, isothiazol-5-yl, isoxazol-4-yl, 1H-pyrazol-3-yl,1H-pyrazol-5-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, pyridin-2-yl,pyridin-3-yl, pyridin-4-yl, or pyrimidin-5-yl. For the substituent Ar²representing “9-membered bicyclic heteroaryl”, the term especially meansindolyl; or, in addition benzothiophenyl, benzothiazolyl, orbenzoimidazolyl; notably 1H-indol-2-yl; or, in addition,benzothiophen-6-yl, benzothiazol-6-yl, benzothiazol-5-yl, orbenzoimidazol-6-yl; wherein said 9-membered bicyclic heteroaryl isunsubstituted or substituted as explicitly defined; a particular exampleis 1-methyl-1H-indol-2-yl. For the substituent Ar² representing“10-membered bicyclic heteroaryl”, the term especially means quinolinylor quinoxalinyl; notably quinoline-2-yl, or quinoxaline-5-yl.

The term “cyano” refers to a group —CN.

Whenever the word “between” is used to describe a numerical range, it isto be understood that the end points of the indicated range areexplicitly included in the range. For example: if a temperature range isdescribed to be between 40° C. and 80° C., this means that the endpoints 40° C. and 80° C. are din n the range; or if a variable isdefined as being an integer between 1 and 4, this means that thevariable is the integer 1, 2, 3, or 4.

Unless used regarding temperatures, the term “about” placed before anumerical value “X” refers in the current application to an intervalextending from X minus 10% of X to X plus 10% of X, and preferably to aninterval extending from X minus 5% of X to X plus 5% of X. In theparticular case of temperatures, the term “about” placed before atemperature “Y” refers in the current application to an intervalextending from the temperature Y minus 10° C. to Y plus 10° C., andpreferably to an interval extending from Y minus 5° C. to Y plus 5° C.Besides, the term “room temperature” as used herein refers to atemperature of about 25° C.

Further embodiments of the invention are presented hereinafter:

2) A second embodiment relates to compounds according to embodiment 1),wherein Ar¹ represents a phenyl which is mono-, di- or tri-substituted,wherein the substituents are independently selected from halogen,methyl, cyano, and methoxy;wherein at least one of said substituents is attached in a meta- or inpara-position of said phenyl,

-   -   wherein, if present, the substituent in para-position is        preferably selected from halogen, methyl, cyano, and methoxy;        and    -   wherein, if present, the substituent in meta-position is        preferably halogen.        3) Another embodiment relates to compounds according to        embodiment 1), wherein Ar¹ represents phenyl which is mono-, di-        or tri-substituted, wherein    -   one of said substituents is attached in meta-position of said        phenyl, wherein said substituent is halogen; and the remaining        substituent(s), if present, is/are halogen (especially fluoro);        or    -   one of said substituents is attached in para-position of said        phenyl, wherein said substituent is independently selected from        methyl, cyano, and methoxy; and the remaining substituent(s), if        present, is/are halogen (especially fluoro).        4) Another embodiment relates to compounds according to        embodiment 1), wherein Ar¹ represents a phenyl group of the        structure

wherein

-   -   R^(o1) represents hydrogen, fluoro, methyl, methoxy or        trifluoromethyl;    -   R^(m1) represents hydrogen or halogen;    -   R^(p) represents hydrogen, halogen, methyl, cyano,        3-hydroxyprop-1-yl or morpholin-4-yl; and    -   R^(m2) represents hydrogen, halogen, methyl, methoxy or        trifluoromethoxy.        5) Another embodiment relates to compounds according to        embodiment 1), wherein Ar¹ represents a phenyl group of the        structure

wherein

-   -   R^(m2) represents hydrogen or fluoro; and    -   R^(p) represents independently halogen (especially fluoro or        chloro), methyl, cyano, or methoxy (notably R^(p) represents        fluoro, chloro, or methyl); or    -   R^(m2) represents hydrogen or fluoro; and R^(p) represents        hydrogen.        6) Another embodiment relates to compounds according to        embodiment 1), wherein Ar¹ represents a phenyl group of the        structure

wherein

-   -   R^(m2) represents halogen (especially fluoro); and    -   R^(p) represents hydrogen, halogen (especially fluoro or        chloro), methyl, cyano, or methoxy (notably R^(p) represents        fluoro, chloro, or methyl).        7) Another embodiment relates to compounds according to        embodiment 1), wherein Ar¹ represents

wherein each of the groups A) to C) form a particular sub-embodiment;and wherein group A) forms another sub-embodiment.8) Another embodiment relates to compounds according to any one ofembodiments 1) to 7), wherein R¹ represents

-   -   hydroxy;    -   methoxy; or    -   —O—CH₂—CO—R^(1X) wherein R^(1X) represents        -   -hydroxy;        -   morpholin-4-yl; or

9) Another embodiment relates to compounds according to any one ofembodiments 1) to 7), wherein R¹ represents hydroxy.10) Another embodiment relates to compounds according to any one ofembodiments 1) to 7) wherein R¹ represents methoxy.11) Another embodiment relates to compounds according to any one ofembodiments 1) to 10), wherein L represents methylene.12) Another embodiment relates to compounds according to any one ofembodiments 1) to 10), wherein L represents a direct bond.13) Another embodiment relates to compounds according to any one ofembodiments 1) to 12), wherein Ar² represents

-   -   phenyl which is unsubstituted, mono-, or di-substituted wherein        the substituents independently are selected from C₁₋₄-alkyl        (especially methyl), C₁₋₃-fluoroalkyl (especially        trifluoromethyl), C₁₋₃-alkoxy (especially methoxy), halogen        (especially fluoro or choro), ethynyl, and cyano; or    -   5- or 6-membered heteroaryl (especially furanyl, thiophenyl,        pyrrolyl, thiazolyl, isothiazolyl, isoxazolyl, pyrazolyl,        imidazolyl, pyridinyl, or pyrimidinyl), wherein said 5- or        6-membered heteroaryl independently is unsubstituted, mono-, or        di-substituted wherein the substituents independently are        selected from C₁₋₄-alkyl (especially methyl),        —CH₂—C₃₋₆-cycloalkyl (especially —CH₂-cyclopropyl),        C₁₋₃-fluoroalkyl (especially trifluoromethyl), C₁₋₃-alkoxy        (especially methoxy), halogen (especially fluoro or chloro),        morpholine-4-yl, and amino.        14) Another embodiment relates to compounds according to any one        of embodiments 1) to 12), wherein Ar² represents:    -   phenyl which is unsubstituted, mono-, or di-substituted wherein        the substituents independently are selected from C₁₋₄-alkyl        (especially methyl), C₁₋₃-fluoroalkyl (especially        trifluoromethyl), C₁₋₃-alkoxy (especially methoxy), halogen        (especially fluoro or choro) and cyano; or    -   a 5- or 6-membered heteroaryl (especially thiophenyl, pyrrolyl,        isothiazolyl, pyrazolyl, pyridinyl, or pyrimidinyl), wherein        said 5- or 6-membered heteroaryl independently is unsubstituted,        mono-, or di-substituted wherein the substituents independently        are selected from C₁₋₄-alkyl (especially methyl),        —CH₂—C₃₋₆-cycloalkyl (especially —CH₂-cyclopropyl),        C₁₋₃-fluoroalkyl (especially trifluoromethyl), C₁₋₃-alkoxy        (especially methoxy), halogen (especially fluoro or choro), and        morpholine-4-yl.        15) Another embodiment relates to compounds according to any one        of embodiments 1) to 12), wherein Ar² represents:    -   phenyl which is mono-, or di-substituted wherein the        substituents independently are selected from C₁₋₃-fluoroalkyl        (especially trifluoromethyl), and halogen; or    -   a 5- or 6-membered heteroaryl (especially thiophenyl, pyrrolyl,        pyrazolyl, pyridinyl, or pyrimidinyl), wherein said 5- or        6-membered heteroaryl independently is mono-, or di-substituted        wherein the substituents independently are selected from        C₁₋₄-alkyl (especially methyl), and C₁₋₃-fluoroalkyl (especially        trifluoromethyl).        16) Another embodiment relates to compounds according to any one        of embodiments 1) to 10), wherein the fragment -L-Ar²        represents:

wherein each of the groups A) to H) form a particular sub-embodiment;and wherein another sub-embodiment refers to groups A), B), and/or C).17) Another embodiment relates to compounds according to any one ofembodiments 1) to 16), wherein n represents the integer 1.18) The invention, thus, relates to compounds of the Formula (I) asdefined in embodiment 1), or to such compounds further limited by thecharacteristics of any one of embodiments 2) to 17), under considerationof their respective dependencies; to pharmaceutically acceptable saltsthereof; and to the use of such compounds as further described hereinbelow. For avoidance of any doubt, especially the following embodimentsrelating to the compounds of Formula (I) are thus possible and intendedand herewith specifically disclosed in individualized form:1, 2+1, 3+1, 4+1, 5+1, 6+1, 7+1, 8+1, 8+2+1, 8+3+1, 8+4+1, 8+6+1, 8+6+1,8+7+1, 9+1, 9+2+1, 9+3+1, 9+4+1, 9+6+1, 9+6+1, 9+7+1, 10+1, 10+2+1,10+3+1, 10+4+1, 10+6+1, 10+6+1, 10+7+1, 11+1, 11+2+1, 11+3+1, 11+4+1,11+6+1, 11+6+1, 11+7+1, 11+8+1, 11+8+2+1, 11+8+3+1, 11+8+4+1, 11+8+6+1,11+8+6+1, 11+8+7+1, 11+9+1, 11+9+2+1, 11+9+3+1, 11+9+4+1, 11+9+6+1,11+9+6+1, 11+9+7+1, 11+10+1, 11+10+2+1, 11+10+3+1, 11+10+4+1, 11+10+6+1,11+10+6+1, 11+10+7+1, 12+1, 12+2+1, 12+3+1, 12+4+1, 12+6+1, 12+6+1,12+7+1, 12−8+1, 12+8+2+1, 12−8+3+1, 12+8+4+1, 12+8+6+1, 12+8+4+1,12−8+7+1, 12+9+1, 12+9+2+1, 12+9+3+1, 12+9+4+1, 12+9+6+1, 12+946+1,12+9+7+1, 12+10+1, 12+10+2+1, 12+10+3+1, 12+10+4+1, 12+10+6+1,12+10+6+1, 12+10+7+1, 13+1, 13+2+1, 13+3+1, 13+4+1, 13+6+1, 13+6+1,13+7+1, 13−8+1, 13+8+2+1, 13+8+3+1, 13+8+4+1, 13+8+6+1, 13+8+6+1,13−8+7+1, 13+9+1, 13+9+2+1, 13+9+3+1, 13+9+4+1, 13+9+6+1, 13+9−6+1,13+9+7+1, 13+10+1, 13+10+2+1, 13+10+3+1, 13+10+4+1, 13+10+6+1,13+10−6+1, 13+10+7+1, 13+11+1, 13+11+2+1, 13+11+3+1, 13+11+4+1,13+11+6+1, 13+11+6+1, 13+11+7+1, 13+11+8+1, 13+11+8+2+1, 13+11+8+3+1,13+11+8+4+1, 13+11+8+6+1, 13+11−8+6+1, 13+11−8+7+1, 13+11+9+1,13+11+9+2+1, 13+11+9+3+1, 13+11+9+4+1, 13+11+9+6+1, 13+11+9+6+1,13+11+9+7+1, 13+11+10+1, 13+11+10+2+1, 13+11+10+3+1, 13+11+10+4+1,13+11+10+6+1, 13+11+10+6+1, 13+11+10+7+1, 13+12+1, 13+12+2+1, 13+12+3+1,13+12+4+1, 13+12+6+1, 13+12+6+1, 13+12+7+1, 13+12+8+1, 13+12+8+2+1,13+12+8+3+1, 13+12+8+4+1, 13+12+8+6+1, 13+12+8+6+1, 13+12+8+7+1,13+12+9+1, 13+12+9+2+1, 13+12+9+3+1, 13+12+9+4+1, 13+12+9+6+1,13+12+946+1, 13+12+9+7+1, 13+12+10+1, 13+12+10+2+1, 13+12+10+3+1,13+12+10+4+1, 13+12+10+5+1, 13+12+10+6+1, 13+12+10+7+1, 14+1, 14+2+1,14+3+1, 14+4+1, 14+6+1, 14+6+1, 14+7+1, 14+8+1, 14+8+2+1, 14+8+3+1,14+8+4+1, 14+8+6+1, 14+8+6+1, 14+8+7+1, 14+9+1, 14+9+2+1, 14+9+3+1,14+9+4+1, 14+9+6+1, 14+9+6+1, 14+9+7+1, 14+10+1, 14+10+2+1, 14+10+3+1,14+10+4+1, 14+10+6+1, 14+10+6+1, 14+10+7+1, 14+11+1, 14+11+2+1,14+11+3+1, 14+11+4+1, 14+11+6+1, 14+11+6+1, 14+11+7+1, 14+11+8+1,14+11+8+2+1, 14+11+8+3+1, 14+11+8+4+1, 14+11+8+6+1, 14+11+8+6+1,14+11+8+7+1, 14+11+9+1, 14+11+9+2+1, 14+11+9+3+1, 14+11+9+4+1,14+11+9+6+1, 14+11+9+6+1, 14+11+9+7+1, 14+11+10+1, 14+11+10+2+1,14+11+10+3+1, 14+11+10+4+1, 14+11+10+6+1, 14+11+10+6+1, 14+11+10+7+1,14+12+1, 14+12+2+1, 14+12+3+1, 14+12+4+1, 14+12+6+1, 14+12+6+1,14+12+7+1, 14+12+8+1, 14+12+8+2+1, 14+12+8+3+1, 14+12+8+4+1,14+12+8+6+1, 14+12+8+6+1, 14+12+8+7+1, 14+12+9+1, 14+12+9+2+1,14+12+9+3+1, 14+12+9+4+1, 14+12+9+6+1, 14+12+9+6+1, 14+12+9+7+1,14+12+10+1, 14+12+10+2+1, 14+12+10+3+1, 14+12+10+4+1, 14+12+10+5+1,14+12+10+6+1, 14+12+10+7+1, 15+1, 15+2+1, 15+3+1, 15+4+1, 15+6+1,15+6+1, 15+7+1, 15+8+1, 15+8+2+1, 15+8+3+1, 15+8+4+1, 15+8+5+1,15+8+6+1, 15+8+7+1, 15+9+1, 15+9+2+1, 15+9+3+1, 15+9+4+1, 15+9+6+1,15+9+6+1, 15+9+7+1, 15+10+1, 15+10+2+1, 15+10+3+1, 15+10+4+1, 15+10+6+1,15+10+6+1, 15+10+7+1, 15+11+1, 15+11+2+1, 15+11+3+1, 15+11+4+1,15+11+6+1, 15+11+6+1, 15+11+7+1, 15+11+8+1, 15+11+8+2+1, 15+11+8+3+1,15+11+8+4+1, 15+11+8+6+1, 15+11+8+6+1, 15+11+8+7+1, 15+11+9+1,15+11+9+2+1, 15+11+9+3+1, 15+11+9+4+1, 15+11+9+6+1, 15+11+9+6+1,15+11+9+7+1, 15+11+10+1, 15+11+10+2+1, 15+11+10+3+1, 15+11+10+4+1,15+11+10+6+1, 15+11+10+6+1, 15+11+10+7+1, 15+12+1, 15+12+2+1, 15+12+3+1,15+12+4+1, 15+12+6+1, 15+12+6+1, 15+12+7+1, 15+12+8+1, 15+12+8+2+1,15+12+8+3+1, 15+12+8+4+1, 15+12+8+6+1, 15+12+8+6+1, 15+12+8+7+1,15+12+9+1, 15+12+9+2+1, 15+12+9+3+1, 15+12+9+4+1, 15+12+9+6+1,15+12+9+6+1, 15+12+9+7+1, 15+12+10+1, 15+12+10+2+1, 15+12+10+3+1,15+12+10+4+1, 15+12+10+6+1, 15+12+10+6+1, 15+12+10+7+1, 16+1, 16+2+1,16+3+1, 16+4+1, 16+6+1, 16+6+1, 16+7+1, 16+8+1, 16+8+2+1, 16+8+3+1,16+8+4+1, 16+8+5+1, 16+8+6+1, 16+8+7+1, 16+9+1, 16+9+2+1, 16+9+3+1,16+9+4+1, 16+9+6+1, 16+9+6+1, 16+9+7+1, 16+10+1, 16+10+2+1, 16+10+3+1,16+10+4+1, 16+10+6+1, 16+10+6+1, 16+10+7+1, 17+1, 17+2+1, 17+3+1,17+4+1, 17+6+1, 17+6+1, 17+7+1, 17+8+1, 17+8+2+1, 17+8+3+1, 17+8+4+1,17+8+5+1, 17+8+6+1, 17+8+7+1, 17+9+1, 17+9+2+1, 17+9+3+1, 17+9+4+1,17+9+6+1, 17+9+6+1, 17+9+7+1, 17+10+1, 17+10+2+1, 17+10+3+1, 17+10+4+1,17+10+6+1, 17+10+6+1, 17+10+7+1, 17+11+1, 17+11+2+1, 17+11+3+1,17+11+4+1, 17+11+6+1, 17+11+6+1, 17+11+7+1, 17+11+8+1, 17+11+8+2+1,17+11+8+3+1, 17+11+8+4+1, 17+11+8+5+1, 17+11+8+6+1, 17+11+8+7+1,17+11+9+1, 17+11+9+2+1, 17+11+9+3+1, 17+11+9+4+1, 17+11+9+6+1,17+11+9+6+1, 17+11+9+7+1, 17+11+10+1, 17+11+10+2+1, 17+11+10+3+1,17+11+10+4+1, 17+11+10+6+1, 17+11+10+6+1, 17+11+10+7+1, 17+12+1,17+12+2+1, 17+12+3+1, 17+12+4+1, 17+12+6+1, 17+12+6+1, 17+12+7+1,17+12+8+1, 17+12+8+2+1, 17+12+8+3+1, 17+12+8+4+1, 17+12+8+5+1,17+12+8+6+1, 17+12+8+7+1, 17+12+9+1, 17+12+9+2+1, 17+12+9+3+1,17+12+9+4+1, 17+12+9+6+1, 17+12+9+6+1, 17+12+9+7+1, 17+12+10+1,17+12+10+2+1, 17+12+10+3+1, 17+12+10+4+1, 17+12+10+5+1, 17+12+10+6+1,17+12+10+7+1, 17+13+1, 17+13+2+1, 17+13+3+1, 17+13+4+1, 17+13+5+1,17+13+6+1, 17+13+7+1, 17+13+8+1, 17+13+8+2+1, 17+13+8+3+1, 17+13+8+4+1,17+13+8+5+1, 17+13+8+6+1, 17+13+8+7+1, 17+13+9+1, 17+13+9+2+1,17+13+9+3+1, 17+13+9+4+1, 17+13+9+6+1, 17+13+9+6+1, 17+13+9+7+1,17+13+10+1, 17+13+10+2+1, 17+13+10+3+1, 17+13+10+4+1, 17+13+10+5+1,17+13+10+6+1, 17+13+10+7+1, 17+13+11+1, 17+13+11+2+1, 17+13+11+3+1,17+13+11+4+1, 17+13+11+5+1, 17+13+11+6+1, 17+13+11+7+1, 17+13+11+8+1,17+13+11+8+2+1, 17+13+11+8+3+1, 17+13+11+8+4+1, 17+13+11+8+5+1,17+13+11+8+6+1, 17+13+11+8+7+1, 17+13+11+9+1, 17+13+11+9+2+1,17+13+11+9+3+1, 17+13+11+9+4+1, 17+13+11+9+6+1, 17+13+11+9+6+1,17+13+11+9+7+1, 17+13+11+10+1, 17+13+11+10+2+1, 17+13+11+10+3+1,17+13+11+10+4+1, 17+13+11+10+5+1, 17+13+11+10+6+1, 17+13+11+10+7+1,17+13+12+1, 17+13+12+2+1, 17+13+12+3+1, 17+13+12+4+1, 17+13+12+5+1,17+13+12+6+1, 17+13+12+7+1, 17+13+12+8+1, 17+13+12+8+2+1,17+13+12+8+3+1, 17+13+12+8+4+1, 17+13+12+8+5+1, 17+13+12+8+6+1,17+13+12+8+7+1, 17+13+12+9+1, 17+13+12+9+2+1, 17+13+12+9+3+1,17+13+12+9+4+1, 17+13+12+9+6+1, 17+13+12+9+6+1, 17+13+12+9+7+1,17+13+12+10+1, 17+13+12+10+2+1, 17+13+12+10+3+1, 17+13+12+10+4+1,17+13+12+10+6+1, 17+13+12+10+6+1, 17+13+12+10+7+1, 17+14+1, 17+14+2+1,17+14+3+1, 17+14+4+1, 17+14+6+1, 17+14+6+1, 17+14+7+1, 17+14+8+1,17+14+8+2+1, 17+14+8+3+1, 17+14+8+4+1, 17+14+8+6+1, 17+14+8+6+1,17+14+8+7+1, 17+14+9+1, 17+14+9+2+1, 17+14+9+3+1, 17+14+9+4+1,17+14+9+6+1, 17+14+9+6+1, 17+14+9+7+1, 17+14+10+1, 17+14+10+2+1,17+14+10+3+1, 17+14+10+4+1, 17+14+10+5+1, 17+14+10+6+1, 17+14+10+7+1,17+14+11+1, 17+14+11+2+1, 17+14+11+3+1, 17+14+11+4+1, 17+14+11+5+1,17+14+11+6+1, 17+14+11+7+1, 17+14+11+8+1, 17+14+11+8+2+1,17+14+11+8+3+1, 17+14+11+8+4+1, 17+14+11+4+86+1, 17+14+11+8+6+1,17+14+11+8+7+1, 17+14+11+9+1, 17+14+11+9+2+1, 17+14+11+9+3+1,17+14+11+9+4+1, 17+14+11+9+6+1, 17+14+11+9+6+1, 17+14+11+9+7+1,17+14+11+10+1, 17+14+11+10+2+1, 17+14+11+10+3+1, 17+14+11+10+4+1,17+14+11+10+5+1, 17+14+11+10+6+1, 17+14+11+10+7+1, 17+14+12+1,17+14+12+2+1, 17+14+12+3+1, 17+14+12+4+1, 17+14+12+5+1, 17+14+12+6+1,17+14+12+7+1, 17+14+12+8+1, 17+14+12+8+2+1, 17+14+12+8+3+1,17+14+12+8+4+1, 17+14+12+4+6+1, 17+14+12+8+6+1, 17+14+12+8+7+1,17+14+12+9+1, 17+14+12+9+2+1, 17+14+12+9+3+1, 17+14+12+9+4+1,17+14+12+9+6+1, 17+14+12+9+6+1, 17+14+12+9+7+1, 17+14+12+10+1,17+14+12+10+2+1, 17+14+12+10+3+1, 17+14+12+10+4+1, 17+14+12+10+6+1,17+14+12+10+6+1, 17+14+12+10+7+1, 17+15+1, 17+15+2+1, 17+15+3+1,17+15+4+1, 17+15+6+1, 17+15+6+1, 17+15+7+1, 17+15+8+1, 17+15+8+2+1,17+15+8+3+1, 17+15+8+4+1, 17+15+8+6+1, 17+15+8+6+1, 17+15+8+7+1,17+15+9+1, 17+15+9+2+1, 17+15+9+3+1, 17+15+9+4+1, 17+15+9+6+1,17+15+9+6+1, 17+15+9+7+1, 17+15+10+1, 17+15+10+2+1, 17+15+10+3+1,17+15+10+4+1, 17+15+10+5+1, 17+15+10+6+1, 17+15+10+7+1, 17+15+11+1,17+15+11+2+1, 17+15+11+3+1, 17+15+11+4+1, 17+15+11+5+1, 17+15+11+6+1,17+15+11+7+1, 17+15+11+8+1, 17+15+11+8+2+1, 17+15+11+8+3+1,17+15+11+8+4+1, 17+15+11+8+5+1, 17+15+11+4+6+1, 17+15+11+8+7+1,17+15+11+9+1, 17+15+11+9+2+1, 17+15+11+9+3+1, 17+15+11+9+4+1,17+15+11+9+5+1, 17+15+11+9+6+1, 17+15+11+9+7+1, 17+15+11+10+1,17+15+11+10+2+1, 17+15+11+10+3+1, 17+15+11+10+4+1, 17+15+11+10+5+1,17+15+11+10+6+1, 17+15+11+10+7+1, 17+15+12+1, 17+15+12+2+1,17+15+12+3+1, 17+15+12+4+1, 17+15+12+5+1, 17+15+12+6+1, 17+15+12+7+1,17+15+12+8+1, 17+15+12+8+2+1, 17+15+12+8+3+1, 17+15+12+8+4+1,17+15+12+8+5+1, 17+15+12+8+6+1, 17+15+12+8+7+1, 17+15+12+9+1,17+15+12+9+2+1, 17+15+12+9+3+1, 17+15+12+9+4+1, 17+15+12+9+5+1,17+15+12+9+6+1, 17+15+12+9+7+1, 17+15+12+10+1, 17+15+12+10+2+1,17+15+12+10+3+1, 17+15+12+10+4+1, 17+15+12+10+6+1, 17+15+12+10+6+1,17+15+12+10+7+1, 17+16+1, 17+16+2+1, 17+16+3+1, 17+16+4+1, 17+16+6+1,17+16+6+1, 17+16+7+1, 17+16+8+1, 17+16+8+2+1, 17+16+8+3+1, 17+16+8+4+1,17+16+8+5+1, 17+16+8+6+1, 17+16+8+7+1, 17+16+9+1, 17+16+9+2+1,17+16+9+3+1, 17+16+9+4+1, 17+16+9+5+1, 17+16+9+6+1, 17+16+9+7+1,17+16+10+1, 17+16+10+2+1, 17+16+10+3+1, 17+16+10+4+1, 17+16+10+5+1,17+16+10+6+1, 17+16+10+7+1.

In the list above the numbers refer to the embodiments according totheir numbering provided hereinabove whereas “+” indicates thedependency from another embodiment. The different individualizedembodiments are separated by commas. In other words, “17+16+7+1” forexample refers to embodiment 17) depending on embodiment 16), dependingon embodiment 7), depending on embodiment 1), i.e. embodiment“17+16+7+1” corresponds to the compounds of formula (I) according toembodiment 1) further limited by all the features of the embodiments 7),16), and 17).

19) Another embodiment relates to compounds of Formula (I) according toembodiment 1), which are selected from the following compounds

-   (2R,3R,4S,5R,6R)—N-benzyl-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-ethynylbenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-phenethyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(4-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(2-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((3-chloropyridin-4-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((4-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-(trifluoromethyl)benzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazo-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(2-chlorobenzyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((3-(trifluoromethyl)pyridin-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((2-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((2-amino-4-chlorothiazol-5-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(isoxazol-4-ylmethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((5-chlorofuran-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(isothiazol-4-ylmethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((2-bromothiazol-4-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)    4(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((2-morpholinothiazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((5-chlorothiophen-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)    4(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((5-chlorothiazol-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-pyrazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((3-(trifluoromethyl)pyridin-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyohexyl)-6-(hydroxymethyl)-3-methoxy-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((4-(trifluoromethyl)pyrimidin-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((4,6-dimethoxypyrimidin-5-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((4-methylpyrimidin-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((5-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((4-chloroisothiazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-pyrazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((3-methylthiophen-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-pyrrol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((3-chlorothiophen-2-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((4-methylthiazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((2-methylthiophen-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-methoxybenzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(2,6-dimethoxybenzyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)—N-((1-ethyl-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-isopropyl-1H-pyrazol-5-yl)methyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((1-(cyclopropylmethyl)-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-indol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triaz-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)—N-(3-chlorobenzyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)—N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;    and-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide.    20) In addition to the compounds listed in embodiment 19), further    compounds according to embodiment 1) are selected from the following    compounds:-   (2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluormethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)—N-((6-fluoro-3-methoxyquinoxalin-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-((3-chloroquinolin-2-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl    acetate;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethylbenzyl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(5-fluoro-2-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyano-5-methylphenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyano-5-methoxyphenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-methylphenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chlorophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyanophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(methoxy-d3)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(5-chloro-2-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-4-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-4-(trifluoromethyl)phenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-4-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-(trifluoromethyl)phenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dibromophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,4-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-4-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-phenyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(benzo[b]thiophen-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(5-chloro-2-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(2,5-dimethylbenzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(2-chlorobenzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(5-bromo-2-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(4-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-(trifluoromethyl)phenyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-fluoro-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-fluoro-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(m-tolyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-methyl-1H-benzo[d]imidazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-6-yl)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-fluorophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-5-yl)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triaz-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triaz-1-yl)-N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-fluorophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyano-5-fluorophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-6-yl)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   2-(((2R,3R,4S,5R,6R)-2-((3-chloro-5-cyanophenyl)((1S,2S)-2-hydroxycyclohexyl)carbamoyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)acetic    acid;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(4,5-difluoro-2-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3-fluoro-4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(4-pyrano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,4-difluoro-5-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyano-5-fluorophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-cyano-5-methoxyphenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-5-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(2-methylbenzo[d]thiazol-6-yl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(4-fluoronaphthalen-1-yl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl)-N-(2,3-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyohexyl)-6-(hydroxymethyl)-3-methoxy-N-(pyridin-2-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(naphthalen-2-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(naphthalen-1-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(1,5-dimethyl-1H-pyrazol-3-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)-4-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycycloheptyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycycloheptyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-((S)-3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-((R)-3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-(4-hydroxypiperidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-3-(2-(3-hydroxyazetidin-1-yl)-2-oxoethoxy)-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   2-(((2R,3R,4S,5R,6R)-2-((3,5-dichlorophenyl)((1S,2S)-2-hydroxycyclohexyl)carbamoyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic    acid;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-morpholinophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;    and-   (2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-((3-hydroxypropyl)amino)phenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide.

The compounds of Formula (I) according to embodiments 1) to 20) andtheir pharmaceutically acceptable salts can be used as medicaments, e.g.in the form of pharmaceutical compositions for enteral (such especiallyoral e.g. in form of a tablet or a capsule) or parenteral administration(including topical application or inhalation).

The production of the pharmaceutical compositions can be effected in amanner which will be familiar to any person skilled in the art (see forexample Remington, The Science and Practice of Pharmacy, 21st Edition(2005), Part 5, “Pharmaceutical Manufacturing” [published by LippincottWilliams & Wilkins]) by bringing the described compounds of Formula (I)or their pharmaceutically acceptable salts, optionally in combinationwith other therapeutically valuable substances, into a galenicaladministration form together with suitable, non-toxic, inert,therapeutically compatible solid or liquid carrier materials and, ifdesired, usual pharmaceutical adjuvants.

The present invention also relates to a method for theprevention/prophylaxis or treatment of a disease or disorder mentionedherein comprising administering to a subject a pharmaceutically activeamount of a compound of Formula (I) according to embodiments 1) to 20).In a sub-embodiment of the invention, the administered amount iscomprised between 1 mg and 1000 mg per day.

For avoidance of any doubt, if compounds are described as useful for theprevention/prophylaxis or treatment of certain diseases, such compoundsare likewise suitable for use in the preparation of a medicament for theprevention/prophylaxis or treatment of said diseases. Likewise, suchcompounds are also suitable in a method for the prevention/prophylaxisor treatment of such diseases, comprising administering to a subject(mammal, especially human) in need thereof, an effective amount of suchcompound.

21) Another embodiment relates to the compounds of formula (I) asdefined in any one of embodiments 1) to 20) which are useful for theprevention/prophylaxis or treatment of diseases and disorders that arerelated to galectin-3 binding to natural ligands.

Such diseases and disorders that are related to Gal-3 binding to naturalligands are especially diseases and disorders in which inhibition of thephysiological activity of Gal-3 is useful, such as diseases in which aGal-3 receptor participates, is involved in the etiology or pathology ofthe disease, or is otherwise associated with at least one symptom of thedisease.

Diseases or disorders that are related to galectin-3 binding to naturalligands may in particular be defined as including:

-   -   fibrosis of organs comprising:        -   all forms of lung/pulmonary fibrosis including all forms of            fibrosing interstitial lung diseases, especially idiopathic            pulmonary fibrosis (alternatively named cryptogenic            fibrosing alveolitis); pulmonary fibrosis secondary to            systemic inflammatory disease such as rheumatoid arthritis,            scleroderma (systemic sclerosis, SSc), lupus (systemic lupus            erythematosus, SLE), polymyositis, or mixed connective            tissue disease (MCTD); pulmonary fibrosis secondary to            sarcoidosis; iatrogenic pulmonary fibrosis including            radiation-induced fibrosis; silicosis-induced pulmonary            fibrosis; asbestos-induced pulmonary fibrosis; and pleural            fibrosis;        -   renal/kidney fibrosis, including renal fibrosis caused            by/associated with chronic kidney disease (CKD), (acute or            chronic) renal failure, tubulointerstitial nephritis, and/or            chronic nephropathies such as (primary) glomerulonephritis            and glomerulonephritis secondary to systemic inflammatory            diseases such as SLE or SSc, diabetes, focal segmental            glomerular sclerosis, IgA nephropathy, hypertension, renal            allograft, and Alport syndrome;        -   all forms of liver/hepatic fibrosis (associated or not with            portal hypertension) including cirrhosis, alcohol-induced            liver fibrosis, nonalcoholic steatohepatitis, biliary duct            injury, primary biliary cirrhosis (also known as primary            biliary cholangitis), infection- or viral-induced liver            fibrosis (e.g. chronic HCV infection), and autoimmune            hepatitis;        -   all forms of heart/cardiac fibrosis, including heart/cardiac            fibrosis associated with cardiovascular diseases, heart            failure, Fabry disease, CKD; diabetes, hypertension, or            hypercholesterolemia;        -   gut fibrosis, including gut fibrosis secondary to SSc, and            radiation-induced gut fibrosis;        -   skin fibrosis, including SSc and skin scarring;        -   head and neck fibrosis, including radiation-induced head and            neck fibrosis;        -   eye/corneal fibrosis, including scarring (e.g. sequelae of            laser-assisted in situ keratomileusis, or trabeculectomy);        -   hypertrophic scarring and keloids, including burn-induced or            surgical hypertrophic scarring and keloids;        -   fibrosis sequelae of organ transplant (including corneal            transplant);        -   and other fibrotic diseases including endometriosis, spinal            cord fibrosis, myelofibrosis, perivascular and aterial            fibrosis; as well as formation of scar tissue, Peyronie's            disease, abdominal or bowel adhesions, bladder fibrosis,            fibrosis of the nasal passages, and fibrosis mediated by            fibroblasts;    -   (acute or chronic) liver diseases and disorders including acute        and chronic viral hepatitis; cirrhosis caused by/associated with        arthritis and vasculitis; metabolic liver diseases caused        by/associated with arthritis, myocarditis, diabetes, or        neurologic symptoms; cholestatic diseases caused by/associated        with hyperlipidaemia, inflammatory bowel disease (IBD), or        ulcerative colitis; liver tumors; autoimmune hepatitis and        cirrhosis caused by/associated with celiac disease, autoimmune        haemolytic anaemia, IBD, autoimmune thyroiditis, ulcerative        colitis, diabetes, glomerulonephritis, pericarditis, autoimmune        thyroiditis, hyperthyroidism, polymyositis, Sjögren syndrome,        panniculitis, alveolitis or alcoholic steatosis; cirrhosis        associated with dementia; cirrhosis associated with peripheral        neuropathy; cirrhosis caused by/associated with oral or        oesophageal cancer; non-alcoholic fatty liver disease        (especially non-alcoholic steatohepatitis) caused by/associated        with obesity, metabolic syndrome or type 2 diabetes; hepatic        blood vessel disorders (including Budd-Chiari syndrome, portal        vein thrombosis, sinusoidal obstruction syndrome); acute and        chronic liver failure (associated or not with portal        hypertension); liver hypofunction;    -   acute kidney injury and chronic kidney disease (CKD) [especially        CKD of stages 1 to 5 as defined by the Kidney Disease Improving        Global Outcomes (KDIGO) Guidelines], in particular CKD (notably        of these stages) caused by/associated with cardiac diseases        (also referred to as cardio-renal syndrome type 1 and type 2),        or caused by/associated with hypertension, or caused        by/associated with diabetes (also referred to as diabetic kidney        disease (DKD), including DKD associated with hypertension),        wherein such diabetes especially is type 1 or type 2 diabetes),        or caused by/associated with inflammatory diseases and disorders        (such as glomerulonephritis and glomerulonephritis secondary to        systemic inflammatory diseases such as SLE or SSc,        tubulo-interstitial nephritis, vasculitis, sepsis, urinary tract        infection), or caused by/associated with polycystic kidney        disease, or caused by/associated with obstructive nephropathy        (including calculi, benign prostatic hyperplasia, prostate        cancer, retroperitoneal pelvic tumor), or caused by/associated        with symptoms associated with neuropathic bladder disease); as        well as acute and chronic renal failure;    -   cardiovascular diseases and disorders (including atherosclerosis        caused by/associated with hypertension, hypercholesterolemia,        diabetes, inflammation, obesity, elderly/age; peripheral        arterial disease caused by/associated with hypertension,        hypercholesterolemia, diabetes, elderly/age; deep venous        thrombosis; pulmonary embolism caused by/associated with obesity        or cancer; aortic aneurysm and dissection caused by/associated        with elderly/age, hypertension, Marfan syndrome, congenital        heart disorders, inflammatory or infectious disorders;        cerebrovascular disease caused by/associated with hypertension,        atrial fibrillation, hypercholesterolemia, diabetes,        elderly/age; coronary heart disease caused by/associated with        hypertension, hypercholesterolemia, diabetes, elderly/age, or        CKD (especially CKD of stages 1 to 5 as defined by the Kidney        Disease Improving Global Outcomes (KDIGO) Guidelines); rheumatic        heart disease caused by/associated with bacterial infection;        heart and vascular tumors; cardiomyopathy and arrythmias;        valvular heart disease (including valvular calcification and        degenerative aortic stenosis); inflammatory heart disease caused        by/associated with infection, carditis, glomerulonephritis,        cancer heart failure (HF) defined as including especially        congestive HF, including in particular systolic HF/HF with        reduced ejection fraction (HFrEF), and diastolic HF/HF with        preserved ejection fraction (HFpEF);    -   interstitial lung diseases and disorders (including        smoking-related interstitial lung disease; interstitial lung        disease associated with/caused by chronic obstructive pulmonary        disease; interstitial pneumonia associated with collagen        vascular disease (including usual interstitial pneumonia), or        pneumonia);    -   cell proliferative diseases and cancers (including solid tumors,        solid tumor metastasis, carcinoma, sarcoma, myeloma (and        multiple myeloma), leukemia, lymphoma, mixed types of cancers,        vascular fibroma, Kaposi's sarcoma, chronic lymphocytic leukemia        (CLL), spinal cord tumors and invasive metastasis of cancer        cells);    -   inflammatory and autoimmune diseases and disorders including        chronic and acute inflammatory and autoimmune diseases and        disorders (in particular including sepsis, Q-fever, asthma,        rheumatoid arthritis, multiple sclerosis, SLE, SSc,        polymyositis, plaque psoriasis (including psoriasis caused        by/associated with NASH), atopic dermatitis, inflammatory        renal/kidney diseases such as nephropathy (including diabetic        nephropathy, glomerulonephritis, tubulointerstitial nephritis),        inflammatory cardiac/heart diseases, inflammatory lung/lung        related diseases; inflammatory liver/liver related diseases;        diabetes (type 1 or type 2) and diabetes related diseases such        as diabetic vasculopathy, diabetic nephropathy, diabetic        retinopathy, diabetic peripheral neuropathy or skin related        condition; viral encephalitis; and COVID-19 and sequelae        thereof);    -   gastrointestinal tract diseases and disorders (including        irritable bowel syndrome (IBS), inflammatory bowel disease        (IBD), gastritis, and abnormal pancreatic secretion);    -   pancreatic diseases and disorders (including pancreatitis, e.g.        associated with cystic fibrosis);    -   abnormal angiogenesis-associated diseases and disorders        (including arterial obstruction);    -   brain-associated diseases and disorders (including stroke and        cerebral haemorrhage);    -   neuropathic pain and peripheral neuropathy;    -   ocular diseases and disorders (including dry eye disease (dry        eye syndrome), macular degeneration (AMD associated with age,        diabetes related disease (diabetic retinopathy), proliferative        vitreoretinopathy (PVR), cicatricial pemphigoid, and glaucoma        (including glaucoma associated with elevated intraocular        pressure, and ocular scarring after glaucoma filtration        surgery), and corneal angiogenesis/neovascularization); and    -   transplant rejection comprising rejection of transplanted organs        such as kidney, liver, heart, lung, pancreas, cornea, and skin;        graft-versus-host diseases brought about by hematopoietic stem        cell transplantation; chronic allograft rejection and chronic        allograft vasculopathy; and sequelae of such transplant        rejection.        22) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of fibrosis        of organs including liver/hepatic fibrosis, renal/kidney        fibrosis, lung/pulmonary fibrosis, heart/cardiac fibrosis,        eye/corneal fibrosis, and skin fibrosis; as well as gut        fibrosis, head and neck fibrosis, hypertrophic scarring and        keloids; and fibrosis sequelae of organ transplant.        23) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of        cardiovascular diseases and disorders.        24) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of acute        kidney injury and chronic kidney disease (CKD).        25) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of (acute or        chronic) liver diseases and disorders.        26) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of        interstitial lung diseases and disorders.        27) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of ocular        diseases and disorders.        28) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of cell        proliferative diseases and cancers.        29) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of chronic or        acute inflammatory and autoimmune diseases and disorders.        30) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of        gastrointestinal tract diseases and disorders.        31) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of pancreatic        diseases and disorders.        32) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of abnormal        angiogenesis-associated diseases and disorders.        33) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of        brain-associated diseases and disorders.        34) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the prevention/prophylaxis or treatment of        neuropathic pain and peripheral neuropathy.        35) A further embodiment relates to the compounds of formula (I)        for use according to embodiment 21) wherein said compounds are        for use in the treatment of transplant rejection.

Preparation of Compounds of Formula (I)

The compounds of Formula (I) can be prepared by well-known literaturemethods, by the methods given below, by the methods given in theexperimental part below or by analogous methods. Optimum reactionconditions may vary with the particular reactants or solvents used, butsuch conditions can be determined by a person skilled in the art byroutine optimisation procedures. In some cases the order of carrying outthe following reaction schemes, and/or reaction steps, may be varied tofacilitate the reaction or to avoid unwanted by-products. In the generalsequence of reactions outlined below, the integer n and the genericgroups R¹, L, Ar¹, and Ar² are as defined for Formula (I). Otherabbreviations used herein are explicitly defined, or are as defined inthe experimental section. In some instances the generic groups R¹, L,Ar¹, and Ar² might be incompatible with the assembly illustrated in theschemes below and so will require the use of protecting groups (Pg). Theuse of protecting groups is well known in the art (see for example“Protective Groups in Organic Synthesis”, T. W. Greene, P. G. M. Wuts,Wiley-Interscience, 1999). For the purposes of this discussion, it willbe assumed that such protecting groups as necessary are in place. Insome cases the final product may be further modified, for example, bymanipulation of substituents to give a new final product. Thesemanipulations may include, but are not limited to, reduction, oxidation,alkylation, acylation, hydrolysis and transition-metal catalysedcross-coupling reactions which are commonly known to those skilled inthe art. The compounds obtained may also be converted into salts,especially pharmaceutically acceptable salts, in a manner known per se.

Compounds of the Formula (I) of the present invention can be preparedaccording to the general sequence of reactions outlined below. Only afew of the synthetic possibilities leading to compounds of Formula (I)are described.

Compounds d Formula (I) are prepared by coupling a compound of Structure1 where R is either hydrogen, a suitable protective group (Pg) or R¹ (asdefined in Formula (I)) with a compound of Structure 2 to give Structure3. The coupling reaction is performed using standard peptide couplingconditions such as DCC, HOBT, or T3P in presence of a base such as TEAor DIPEA in a suitable solvent such as DCM or DMF or mixtures thereof.Alternatively, POCl₃ can be used with pyridine as a base. In Structure 2and 3, Pg is a suitable protective group such as acetyl, trimethylsilyl(TMS) or tert-butyl dimethylsilyl (TBS), or benzyl, which are well knownto the person skilled in the art. The hydroxy groups in position 4 and 6of Structure 1 can be protected with cyclic protective groups such asisopropylidene, benzylidene or bis-tert-butyl silyl groups. R is eitherhydrogen, a suitable protective group (Pg) or R¹ (as defined in Formula(I)). Compounds of Structure 3 are then deprotected to yield compoundsof Formula (I).

In the case Pg represents an acyl protective group, such a protectivegroup can be cleaved under standard conditions, e.g. by water or analcohol in the presence or absence of additional solvents such as THF,dioxane, etc. and in the presence of a base such as K₂CO₃, NaOH, LiOH.In the case wherein such a protective group represents a benzyl group,the protective group can be cleaved e.g. by hydrogen in the presence ofa catalyst such as Pd/C, PtO₂ in methanol, EA, THF, etc. or mixturesthereof, or by BBr₃ in a solvent such as DCM. In the case wherein such aprotective group is TMS or TBS, the protective group is cleaved usingfluoride ions such as TBAF of HF in pyridine. Alternatively, silylprotective groups are removed under mild acidic conditions such asaqueous acetic acid at temperatures between rt and reflux. In the casewhere Pg is a cyclic protective group such as isopropylidene,benzylidene and bis-tert-butyl silylene group, the cleavage can beperformed under acidic conditions using aqueous acetic acid or TFA.

The compounds of Structure 1 are prepared by hydrolysis of the nitrilefunction in Structure 4 to the carboxylic acid using aqueous acidic(conc. HCl) or basic (NaOH) conditions at temperatures between 20 and100° C., followed by suitable protection or modification of the freehydroxyl groups. Structure 4 in turn is obtained e.g. by reacting acompound of Structure 5 with a compound of Structure 6 in the presenceof CuI and DIPEA in solvents such as THF or DMF (Click Chemistry inGlycoscience: New Development and Strategies, 1st Edition, 2013, JohnWiley& Sons), alternatively the reaction can be run on a commercialcontinuous-flow reactor (Vapourtec) using a copper coil in a solventsuch as THF. Compounds of Structure 6 are either commercially availableor can be prepared according to procedures known to a person skilled inthe art (Synthesis 2011, 22, 3604-3611). Compounds of Structure 5 can beprepared from corresponding gulofuranose derivatives through methodswell known to a person skilled in the art (Carbohydrate Research 1994,251, 33-67; Bioorg. Med. Chem. 2002, 10, 1911-2013).

Compounds of Structure 2 are obtained by protection of compounds ofStructure 7 with a suitable silyl-based protective group under standardconditions. Compounds of Structure 7 are obtained by functionalizationof (1S,2S)-trans-2-aminocyclohexanol or(1S,2S)-trans-2-aminocycloheptanol e.g. by reductive amination using asuitable carbonyl component and a reducing agent such as NaB(OAc)₃H orNaCNBH₃ in a suitable solvent such as DCM, MeOH, THF, DMF or mixturesthereof. Alternatively, compounds of Structure 7 are obtained byreaction of cyclohexene oxide or cycloheptene oxide with an amine. Thisreaction either yields racemic trans-aminoalcohols or when carried outwith a suitable catalyst such as reported in Org. Lett. 2014, 16,2798-2801, the enantiomerically enriched derivatives. In the case thatcompounds of Structure 7 are used in racemic form, the diastereomers ofStructure 3 or Formula 1 can be separated after the coupling withcompounds of Structure 1 using techniques which are well known to theperson skilled in the art, such as chiral preparative HPLC or columnchromatography on SiO₂.

Whenever the compounds of Formula (I) are obtained in the form ofmixtures of stereoisomers, the stereoisomers can be separated bypreparative HPLC using achiral or chiral stationary phases such as aWaters XBridge C18.10 μm OBD, 30×75 mm, or Daicel ChiralCel OJ-H (5-10μm) column, a Daicel ChiralPak IH (5 μm) or AS-H (5 μm) or IB (5 μm)column, respectively. Typical conditions of chiral HPLC are an isocraticmixture of eluent A (CO₂) and eluent B (DCM/MeOH, 0.1% Et₂NH in EtOH,MeOH, EtOH), at a flow rate of 0.8 to 160 mL/min).

EXPERIMENTAL PART

The following examples illustrate the invention but do not at all limitthe scope thereof.

All temperatures are stated in ° C. Commercially available startingmaterials were used as received without further purification. Unlessotherwise specified, all reactions were carried out under an atmosphereof nitrogen or argon. Compounds were purified by flash chromatography onsilica gel (Biotage), by prep TLC (TLC-plates from Merck, Silica gel 60F₂₅₄) or by preparative HPLC. Compounds described in the invention arecharacterized by ¹H-NMR (Bruker Avance II, 400 MHz Ultra Shield™ orBrooker Avance 11 HD, Ascend 500 MHz); chemical shifts are given in ppmrelative to the solvent used; multiplicities: s=singlet, d=doublet,t=triplet, q=quadruplet, quint=quintuplet, hex=hexet, hept=heptet,m=multiplet, br=broad, coupling constants are given in Hz) and/or byLCMS (retention time t_(R) is given in min; molecular weight obtainedfor the mass spectrum is given in g/mol) using the conditions listedbelow.

Characterization methods used:

The LC-MS retention times have been obtained using the following elutionconditions:

A) LC-MS (A):

Zorbax RRHD SB-Aq, 1.8

m, 2.1×50 mm column thermostated at 40° C. The two elution solvents wereas follows: solvent A=water+0.04% TFA; solvent B=acetonitrile. Theeluent flow rate was 0.8 mL/min and the characteristics of the elutingmixture proportion in function of the time t from start of the elutionare summarized in the table below (a linear gradient being used betweentwo consecutive time points):

t (min) 0 0.01 1.20 1.90 2.10 Solvent A (%) 95 95 5 5 95 Solvent B (%) 55 95 95 5 Detection: UV at 210 nm.

B) LC-MS (B):

Waters BEH C18, 1.8

m, 1.2*50 mm column thermostated at 40° C. The two elution solvents wereas follows: solvent A=water+13 mM NH4OH; solvent B=acetonitrile. Theeluent flow rate was 0.8 mL/min and the characteristics of the elutingmixture proportion in function of the time t from start of the elutionare summarized in the table below (a linear gradient being used betweentwo consecutive time points):

t (min) 0 0.01 1.20 1.90 2.00 Solvent A (%) 95 95 5 5 95 Solvent B (%) 55 95 95 5 Detection: UV at 210 nm.

D) LC-MS (D):

Acquity UPLC CSH C18 1.7 um, 2.1×50 mm from Waters column thermostatedat 60° C. The two elution solvents were as follows: solventA=water+0.05% Formic Acid; solvent B=acetonitrile. The eluent flow ratewas 1 mL/min and the characteristics of the eluting mixture proportionin function of the time t from start of the elution are summarized inthe table below (a linear gradient being used between two consecutivetime points):

t (min) 0 1.50 1.90 1.95 4.90 5.00 Solvent A (%) 98 5 5 98 98 50 SolventB (%) 2 95 95 2 2 50 Detection: UV 214 nm.

E) LC-MS (E):

Acquity UPLC CSH C18 1.7 um, 2.1×50 mm from Waters column thermostatedat 60° C. The two elution solvents were as follows: solventA=water+0.05% Formic acid; solvent B=acetonitrile+0.045% Formic acid.The eluent flow rate was 1 mL/min and the characteristics of the elutingmixture proportion in function of the time t from start of the elutionare summarized in the table below (a linear gradient being used betweentwo consecutive time points):

t (min) 0 1.50 1.90 1.95 4.90 5.00 Solvent A (%) 98 5 5 98 98 50 SolventB (%) 2 95 95 2 2 50 Detection: UV 214 nm

The purifications by preparative LC-MS have been performed using theconditions described hereafter.

C) Preparative LC-MS (I):

A Waters column (Waters XBridge C18.10 μm OBD, 30×75 mm) was used. Thetwo elution solvents were as follows: solvent A=water+0.5% of a solutionof 25% NH4OH in water; solvent B=acetonitrile. The eluent flow rate was75 mL/min and the characteristics of the eluting mixture proportion infunction of the time t from start of the elution are summarized in thetables below (a linear gradient being used between two consecutive timepoints):

t (min) 0 0.01 4.0 6.0 6.2 6.6 Solvent A (%) 90 90 5 5 90 90 Solvent B(%) 10 10 95 95 10 10 Detection 210 nm.

Abbreviations (as Used Herein)

ABTS 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acidAcOH acetic acidaq. aqueousBu butyl (such as in nBuLi=n-butyl lithium)Ca circaCC column chromatography on silicaconc. ConcentratedCSA 10-Camphorsulfonic acidDBU 1,8-diazabicyclo[5.4.0]undec-7-eneDCM dichloromethaneDEAD diethyl azodicarboxylateDIPEA N-ethyl diisopropyl amineDMAP 4-dimethylamino pyridineDMF dimethylformamideDMSO dimethylsulfoxideEA ethyl acetateEDC HCl N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochlorideeq (molar) equivalent(s)Et ethylEtOH ethanolEt₂O diethyl etherFC flash chromatographyh hour(s)HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxid hexafluorophosphateHept heptaneHOBt 1-hydroxybenzotriazole hydrateHPLC high performance liquid chromatographyhv high vacuumLAH lithium aluminium hydrideLDA lithium diisopropylamideLC liquid chromatographyM molarity [mol L⁻¹]Me methylMeCN acetonitrileMeOH methanolMS mass spectroscopymin minute(s)N normalityNaOMe sodium methoxideNaOtBu sodium tert. (tertiary) butoxideOD optical densityo/n over nightorg. organicp-ABSA p-acetamidobenzenesulfonyl azidePd(Ph₃)₄ tetrakis(triphenylphosphine)palladium(0)PPh₃ triphenylphosphinePh phenylPTSA p-Toluenesulfonic acidrt room temperaturesat saturatedTBME tert-butylmethyletherTBTU O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroboratetBu tert-butyl=tertiary butylTEA triethylamineTf trifluoromethanesulfonateTFA trifluoroacetic acidTHF tetrahydrofuranTMS trimethylsilylT3P propylphosphenic anhydridet_(R) retention time

A—Preparation of Precursors and Intermediates

The following precursors have been prepared for the synthesis of thecompounds:

Intermediate 1:(3R,4S,5R,6R)-6-(Acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyltriacetate

(3R,4S,5R,6R)-6-(acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyltriacetate is synthesized from(3aR,5S,6S,6aR)-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-olfollowing the literature procedures from Ref: Carbohydrate Research1994, 251, 33-67 and references cited therein.

Intermediate 2:(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-6-cyano-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyldiacetate

Intermediate 1 (10000 mg, 26.5 mmol, 1 eq) is dissolved in nitromethane(4 vol.) (40 mL) and trimethylsilyl cyanide 98% (10.2 mL, 79.6 mmol, 3eq) and boron trifluoride diethyl etherate (3.93 mL, 31.8 mmol, 1.2 eq)are added portionwise over 30 min. Temperature is kept below 35° C. witha water bath. The mixture is stirred at rt for 2 h. The mixture ispartitioned between water (400 mL), sat aq. bicarbonate (100 mL) andTBME (300 mL). The aq phase is extracted once more with TBME (200 mL)and org. phases washed twice with water/brine (ca. 5:1) and brine, driedover MgSO₄. TBME is evaporated on Rotavap at 20° C. The crudeintermediate is purified by filtration over SiO₂ (150 mL cartridgefilled 3/4, DCM/TBME 10:1). The intermediate is used immediately in thenext step.

1H NMR (500 MHz, DMSO) δ: 5.47 (dd, J¹=0.7 Hz, J²=3.2 Hz, 1H), 5.17 (t,J=10.3 Hz, 1H), 5.04 (d, J=10.1 Hz, 1H), 4.22 (dd, J¹=3.2 Hz, J²=10.4Hz, 1H), 4.15 (ddd, J¹=0.8 Hz, J²=4.5 Hz, J³=7.2 Hz, 1H), 4.03-4.08 (m,1H), 3.97 (dd, J¹=7.4 Hz, J²=11.7 Hz, 1H), 2.18 (s, 3H), 2.15 (m, 3H),2.04 (s, 3H)

Intermediate 3a:(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-6-cyano-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyldiacetate

Intermediate 2 is dissolved in DMF (80 mL) and5-ethynyl-1,2,3-trifluorobenzene (312 mg, 21.2 mmol, 0.8 eq), DIPEA(13.6 mL, 79.6 mmol, 3 eq) and CuI (505 mg, 2.65 mmol, 0.1 eq) are addedunder N₂. The yellow mixture is stirred at rt for 1 h. Exothermic. Theyellow solution is slowly poured on water (800 mL) and stirred for 10min. The beige precipitate is filtered off and the filtrate discarded.The beige solid is washed with MeOH and then dissolved in EA (300 mL)and stirred for 10 min. The fine Cu residues are filtered off and thefiltrated is washed with NH4Cl solution (half saturated) and brine,dried over MgSO₄ and concentrated. The residue is triturated with MeOH(ca 100 mL), filtered and dried at hv to give the desired intermediate3a as a beige solid

¹H NMR (500 MHz, DMSO-d6) δ: 8.85 (s, 1H), 7.81-7.85 (m, 2H), 5.91 (m,1H), 5.64 (dd, J1=3.1 Hz, J2=11.0 Hz, 1H), 5.51 (dd, J1=0.7 Hz, J2=3.0Hz, 1H), 5.24 (d, J=9.9 Hz, 1H), 4.43-4.46 (m, 1H), 4.03-4.12 (m, 2H),2.10 (s, 3H), 2.04 (m, 3H), 1.94 (m, 3H). LCMS (A): t_(R)=0.86 min;[M+H]⁺=577.28

Intermediate 3b:(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-6-cyano-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyldiacetate

Prepared in analogy to Intermediate 3a using the appropriate alkynederivative (commercial). LCMS (A): t_(R)=0.95 min; [M+H]+=479.23

Intermediate 3c:(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-cyanotetrahydro-2H-pyran-3,5-diyldiacetate

Prepared in analogy to Intermediate 3a using the appropriate alkynederivative (commercial). LCMS (A): t_(R)=1.00 min; [M+H]+=513.28

Intermediate 3d:(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-6-cyano-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyldiacetate

Prepared in analogy to Intermediate 3a using the appropriate alkynederivative (commercial). LCMS (A): t_(R)=0.98 min; [M+H]+=493.26

Intermediate 3e:(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-6-cyano-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyldiacetate

Prepared in analogy to Intermediate 3a using the appropriate alkynederivative (commercial). LCMS (A): t_(R)=0.91 min; [M+H]+=461.18

Intermediates 3 are further functionalised as shown in the scheme below

Intermediate 4a:(2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxylicacid

Intermediate 3a (2800 mg, 5.64 mmol, 1 eq) is suspended in HCl 25% (20.6mL, 169 mmol, 30 eq) and heated at reflux for 1.5 h. The solution isapplied to a MCI® gel column (ca 100 mL gel) under water. The column iseluted with water until neutral pH (5 fractions a 40 mL). The compoundis then eluted with H₂O/MeCN (3:1). Fractions of 40 mL are taken.Fractions containing product are first concentrated in vacuo to removeMeCN and then freeze-dried to give the title compound as a colourlesssolid.

LCMS (A): t_(R)=0.59 min; [M+H]+=390.22

¹H NMR (500 MHz, DMSO-d6) δ: 12.88-12.90 (br, 1H), 8.79 (s, 1H), 7.86(dd, J¹=6.8 Hz, J²=9.1 Hz, 2H), 5.43-5.46 (m, 1H), 5.30 (d, J=6.2 Hz,1H), 4.84 (dd. J¹=3.0 Hz, J²=10.8 Hz, 1H), 4.72 (d, J=0.5 Hz, 1H), 4.36(t, J=10.0 Hz, 1H), 3.94 (dd, J¹=3.0 Hz, J²=6.0 Hz, 1H), 3.85 (d, J=9.4Hz, 1H), 3.71 (t, J=6.5 Hz, 1H), 3.48-3.55 (m, 2H)

Intermediate 4b:(2R,3R,4S,5R,6R)-4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxylicacid

Prepared in analogy to Intermediate 4a LCMS (A): t_(R)=0.55 min;[M+H]+=371.90

Intermediate 4c:(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxylicacid

Prepared in analogy to Intermediate 4a. LCMS (A): t_(R)=0.64 min;[M+H]+=406.20

Intermediate 4d:(2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxylicacid

Prepared in analogy to Intermediate 4a LCMS (A): t_(R)=0.61 min;[M+H]+=386.17

Intermediate 4e:(2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxylicacid

Prepared in analogy to Intermediate 4a LCMS (A): t_(R)=0.50 min;[M+H]+=354.11

Intermediate 5a:(4aR,6R,7R,8R)-7-hydroxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Intermediate 4a (1780 mg, 4.57 mmol, 1 eq) is dissolved in THF (80 mL)and 2,2-dimethoxypropane (1.17 mL, 9.14 mmol, 2 eq) is added followed byPTSA monohydrate (16.1 mg, 0.0914 mmol, 0.02 eq) at rt.

The mixture is heated to 75° C. for 1.5 h and 20-25 mL solvent aredistilled off using a Dean-Stark. The solution is cooled to rt and isthen diluted with EA and washed with 10% citric acid solution, water andbine. The org. layer is dried over MgSO₄, filtered and concentratedunder reduced pressure to give the title intermediate as a beige solid.

LCMS (A): t_(R)=0.8 min; [M+H]+=430.20

1H NMR (500 MHz, DMSO) δ: 12.85-13.10 (m, 1H), 8.67 (s, 1H), 7.88 (dd,J¹=9.1 Hz, J²=6.8 Hz, 2H), 5.45-5.59 (m, 1H), 4.98 (dd, J¹=10.7 Hz,J²=3.4 Hz, 1H), 4.32-4.38 (m, 2H), 4.01-4.03 (m, 1H), 3.94 (d, J=9.3 Hz,1H), 3.71-3.76 (m, 2H), 1.32 (s, 3H), 1.21 (s, 3H)

Intermediate 5b:(4aR,6R,7R,8R,8aR)-8-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Prepared in analogy to Intermediate 5a LCMS (A): t_(R)=0.76 min;[M+H]⁺=412.29

Intermediate 5c:(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Prepared in analogy to Intermediate 5a LCMS (A): t_(R)=0.84 min;[M+H]+=446.24

Intermediate 5d:(4aR,6R,7R,8R,8aR)-8-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Prepared in analogy to Intermediate 5a LCMS (A): t_(R)=0.81 min;[M+H]+=426.27

Intermediate 5e:(4aR,6R,7R,8R,8aR)-8-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Prepared in analogy to Intermediate 5a LCMS (A): t_(R)=0.72 min;[M+H]+=394.19

Intermediate 6a:(4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid Step 1: methyl(4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate

A solution of Intermediate 5a (3180 mg, 7.41 mmol, 1 eq) in DMF (dry)(14.8 mL) and THF (dry) (29.6 mL) is cooled to 0° C. and dimethylsulfate*99.8% (1.44 mL, 15.2 mmol, 2.05 eq) is added followed by NaH(55% dispersion in mineral oil) (622 mg, 15.6 mmol, 2.1 eq). The mixtureis stirred at 0° C. for 30 min and then at rt for 3 h. The mixture iscooled to 0° C. again and quenched by addition of sat. NH₄Cl solution.The mixture is diluted with water and EA and the layers are separated.The org. layer is washed with water and brine and the aq. layer is oncere-extracted with EA. The combined org. layers are dried over magnesiumsulfate, filtrated and evaporated. The residue is precipitated fromTBME/Hept and the colorless solid is filtered off and washed with littleTBME and dried at hv. The desired methylester is isolated as acolourless solid. *Iodomethane could be used as reagent as welldelivering the same product.

LCMS (A): t_(R)=0.98 min; [M+H]+=458.22

Step 2:(4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3d]dioxine-6-carboxylicacid

The intermediate from step 1 (1546 mg, 3.38 mmol, 1 eq) is dissolved inTHF/MeOH/H₂O 3:2:1 (34.1 mL) and lithium hydroxide monohydrate (217 mg,5.07 mmol, 1.5 eq) is added at rt.

The mixture is stirred at rt for 4 h. The mixture is diluted with water,acidified with 0.1N HCl and two times extracted with EA. The org. layersare washed with brine, combined, dried over magnesium sulfate, filteredand concentrated. The residue is triturated in TBME. The white solid isfiltered off and washed with TBME and dried at hv to give the desiredintermediate as a colourless solid.

LCMS (A): t_(R)=0.87 min; [M+H]+=444.25

Intermediate 6b:(4aR,6R,7R,8S,8aR)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)-7-((trimethylsilyl)oxy)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

To a solution of Intermediate 5a (2000 mg, 4.66 mmol, 1 eq) and2,6-lutidine (0.192 mL, 1.63 mmol, 3.5 eq) in DCM dry (5 mL) is dropwiseadded trimethylsilyl trifluoromethanesulfonate (0.255 mL, 1.4 mmol, 3eq) at 0° C. The mixture is stirred at 0° C. for 4.5 h. 2,6-lutidine(1.09 mL, 9.32 mmol, 2 eq) and trimethylsilyl trifluoromethanesulfonate(1.69 mL, 9.32 mmol, 2 eq) are added again at 0° C. and stirring iscontinued at 0° C. 2,6-lutidine (1.09 mL, 9.32 mmol, 2 eq) andtrimethylsilyl trifluoromethanesulfonate (0.506 mL, 2.79 mmol, 0.6 eq)are added again and stirring continued for 1 h. The mixture is dilutedwith DCM and quenched with water at 0° C. The layers are separated andthe org. one is washed with water and brine. The org. layer is filteredover a phase separator and evaporated. The crude is dried at hv and usedwithout purification due to its instability.

Intermediate 6c:(4aR,6R,7R,8S,8aR)-7-((tert-butyldimethylsilyl)oxy)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

To a solution of Intermediate 5a (50 mg, 0.116 mmol, 1 eq) in DCM dry (1mL) under N₂ at 0° C. is added 2,6-lutidine (0.0274 mL, 0.233 mmol. 2eq), followed by addition of tert-butyldimethylsilyltrifluoromethanesulfonate (0.03 mL, 0.128 mmol, 1.1 eq). The orangesolution is then stirred at 0° C. for 1.5 h. The mixture is stirred atrt o/n. tert-butyldimethylsilyl trifluoromethanesulfonate (0.0267 mL,0.116 mmol, 1 eq) and 2,6-lutidine (0.0271 mL, 0.233 mmol, 2 eq) areadded again at 0° C. and the mixture is stirred at 0° C. for 1 h. Themixture is quenched with 10% citric acid and two times extracted withDCM. The combined org. layers are dried using a phase separator and arethen concentrated under reduced pressure. The mixture is dissolved inMeCN/water 1/1 (1 mL) and is treated with HCOOH (0.5 mL). The suspensionis stirred at rt for 1 h and is then filtered. The solid is purified byFC using CombiFlash (4 g SiO₂ column; gradient: hept to hept/EA 1/2 in15 min) to give the desired product as a colourless solid.

LCMS (A): t_(R)=1.07 min; [M+H]+=544.30

Intermediate 6d:(4aR,6R,7R,8S,8aR)-7-acetoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

To a solution of Intermediate 5a (500 mg, 1.16 mmol, 1 eq) in DCM (11.6mL) and TEA (0.648 mL, 4.66 mmol, 4 eq) is added Ac₂O (0.22 mL, 2.33mmol, 2 eq) followed by DMAP (14.2 mg, 0.116 mmol, 0.1 eq). The mixtureis stirred at rt o/n. The mixture is diluted with water and DCM. The pHis carefully adjusted to 5-6 with 10% citric acid and the layers areseparated. The aq. layer is once reextracted with DCM and the combinedorg. layers are dried over MgSO₄, filtered and evaporated. The residueis precipitated from TBME/hept+little MeOH. The colourless solid isfiltered off and washed with TBME to give the desired intermediate as acolourless solid.

LCMS (A): t_(R)=0.87 min; [M+H]+=472.11

Intermediate 6e:(4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Prepared form 5b in analogy to Intermediate 6d. LCMS (A): t_(R)=0.83min; [M+H]+=454.01

Intermediate 6f:(4aR,6R,7R,8S,6aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicadd

Prepared form 5c in analogy to Intermediate 6d. LCMS (A): t_(R)=0.90min; [M+H]+=487.96

Intermediate 6g:(4aR,6R,7R,8S,6aR)-7-acetoxy-8-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Prepared form 5d in analogy to Intermediate 6d. LCMS (A): t_(R)=0.88min; [M+H]+=468.09

Intermediate 6 h:(4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

Prepared form 5e in analogy to Intermediate 6d. LCMS (A): t_(R)=0.79min; [M+H]+=436.04

Intermediate 7a:(2R,3R,4S,5R,6R)-3,5-diacetoxy-6-(acetoxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxylicacid

To a suspension of Intermediate 4a (1500 mg, 3.85 mmol, 1 eq) in Ac₂O(2.04 mL, 21.2 mmol, 5.5 eq) is added perchloric acid 70% in water(0.00831 mL, 0.0963 mmol, 0.025 eq) at 0° C. The mixture is stirred at0° C. for 5 min and then allowed to warm to rt and stirred o/n. Themixture is cooled to 0° C. and diluted with water (50 mL) and THF (5mL). The mixture is allowed to warm to rt (26° C., hydrolysisexothermic).

The mixture is cooled to 0-5° C. and the precipitated product isfiltered off, washed with water and dried at hv o/n to afford theproduct as a white solid.

LCMS (A): t_(R)=0.85 min; [M+H]+=516.13

¹H NMR (500 MHz, DMSO-d6) δ: 13.38 (d, 1H), 8.84 (s, 1H), 7.70-7.95 (m,2H), 5.73 (dd, J¹=11.0 Hz, J²=9.5 Hz), 5.67 (dd, J¹=11.1 Hz, J²=3.2 Hz),5.42-5.45 (m, 1H), 4.37-4.42 (m, 1H), 4.36 (d, J=9.5 Hz, 1H), 4.08 (dd,J¹=11.5 Hz, J²=5.6 Hz, 1H), 4.04 (dd. J¹=11.5 Hz, J²=7.0 Hz, 1H), 2.08(s, 3H), 2.01 (s, 3H), 1.82 (s, 3H)

Intermediate 8a:(2S,4aR,6R,7R,8R,8aR)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-8-carboxylicacid

Intermediate 4a (1 g, 2.57 mmol) is dissolved in MeCN (50 mL).Benzaldehyde dimethylacetal (1 mL) is added followed by PTSA (0.035 g,0.07 eq). The mixture is stirred at rt for 16 h. Volatiles are removedunder reduced pressure and the residue partitioned between EA and sat.NH₄Cl solution. The org phase is dried over MgSO₄ and concentrated togive the desired intermediate as a colourless solid.

LCMS (A): t_(R)=0.89 min; [M+H]+=478.17

¹H NMR (500 MHz, DMSO-d6) δ: 12.17-13.30 (m, 1H), 8.89 (s, 1H), 7.84(dd, J¹=9.0 Hz, J²=6.8 Hz, 2H), 7.32-7.36 (m, 4H), 5.54 (s, 1H), 5.15(dd, J¹=10.7 Hz, J²=3.5 Hz, 1H), 4.45-4.52 (m, 2H), 4.08-4.16 (m, 2H),4.02 (d, J=9.4 Hz, 1H), 3.93 (m, 1H)

Intermediate 9a:(2S,4aR,6R,7R,8S,8aR)-7-acetoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-8-carboxylicacid

Intermediate 8a (1.13 g, 2.37 mmol, 1 eq) is dissolved in DCM (30 mL)and TEA (1.3 mL, 9.47 mmol, 4 eq) and acetic anhydride (0.447 mL, 4.73mmol, 2 eq) are added. The mixture is stirred at rt o/n. Sat. NH₄Clsolution (20 mL) is added and the resulting mixture is stirred at rt for10 min. The resulting precipitate is filtered off and washed with DCMand water. The crude product is dried at hv still containing some salts.The solid is therefore washed with citric acid solution (10%) and waterand dried again at hv.

LCMS (A): t_(R)=0.94 min; [M+H]+=520.16

Preparation of Intermediates of Structure 7 and Structure 2

Intermediates of Structure 7 are prepared by a) reductive amination of2-aminocyclohexanol or 2-aminocycloheptanol with an aldehyde, b) byalkylation with an alkylhalogenide or c) by epoxide opening as shownbelow

Intermediate 10: (1S,2S)-2-((3-chlorobenzyl)amino)cyclohexan-1-ol

To a solution of is-2-aminocyclohexanol hydrochloride (100 mg, 0.868mmol, 1 eq) in DCM/MeOH 4/1 (2.5 mL) is added 3-chlorobenzaldehyde(0.109 mL, 0.955 mmol, 1.1 eq) at rt. To the resulting solution is addedsodium cyanoborohydride (68.9 mg, 1.04 mmol, 1.2 eq) under nitrogen atrt and the solution is stirred at rt for 4 h. Sodium cyanoborohydride(28.7 mg, 0.434 mmol, 0.5 eq) is added again at rt and the mixture isstirred at rt overnight. The mixture is quenched with water and basifiedwith 25% aq. NH₄OH solution. The mixture is extracted twice with DCM andthe combined org. layers are evaporated. The residue is re-dissolved inMeCN and basified with aq. 25% NH₄OH solution. The product is purifiedby prep LCMS (I). Product containing fractions are freeze-dried to givethe desired amino alcohol as a colourless solid.

LCMS (A): t_(R)=0.58 min; [M+H]+=240.25

The following intermediates are prepared in analogy the procedure ofIntermediate 10

t_(R) [min] MS Data Intermediate Compound (LC-MS) m/z [M + H]⁺ 11(1S,2S)-2-((3-ethynylbenzyl)amino)cyclohexan-1-ol 0.58 (A) 230.33 12(1S,2S)-2-(phenethylamino)cyclohexan-1-ol 0.56 (A) 220.38 13(1S,2S)-2-((4-chlorobenzyl)amino)cyclohexan-1-ol 0.57 (A) 240.27 14(1S,2S)-2-((2-chlorobenzyl)amino)cyclohexan-1-ol 0.56 (A) 240.28 15(1S,2S)-2-((2-(trifluoromethyl)benzyl)amino)cyclohexan-1-ol 0.6 (A)274.01 16 (1S,2S)-2-(((3-chloropyridin-4-yl)methyl)amino)cyclohexan-1-ol0.44 (A) 241.26 17 (1S,2S)-2-(((2-(trifluoromethyl)pyridin-3- 0.49 (A)275.23 yl)methyl)amino)cyclohexan-1-ol 18(1S,2S)-2-(((4-(trifluoromethyl)pyridin-3- 0.49 (A) 275.23yl)methyl)amino)cyclohexan-1-ol 19(1S,2S)-2-(((3-(trifluoromethyl)pyridin-2- 0.55 (A) 275.24yl)methyl)amino)cyclohexan-1-ol 20(1S,2S)-2-(((2-methyl-1H-imidazol-4-yl)methyl)amino)cyclohexan- 0.46 (B)210.35 1-ol 21 (1S,2S)-2-(((2-amino-4-chlorothiazol-5- 0.6 (B) 262.16yl)methyl)amino)cyclohexan-1-ol 22(1S,2S)-2-((isoxazol-4-ylmethyl)amino)cyclohexan-1-ol 0.53 (B) 197.36 23(1S,2S)-2-(((5-chlorofuran-2-yl)methyl)amino)cyclohexan-1-ol 0.8 (B)230.22 24 (1S,2S)-2-((isothiazol-4-ylmethyl)amino)cyclohexan-1-ol 0.57(B) 213.17 25(1S,2S)-2-(((1-methyl-1H-imidazol-4-yl)methyl)amino)cyclohexan- 0.49 (B)210.26 1-ol 26(1S,2S)-2-(((2-bromothiazol-4-yl)methyl)amino)cyclohexan-1-ol 0.71 (B)291.13 27 (1S,2S)-2-(((2-morpholinothiazol-5-yl)methyl)amino)cyclohexan-0.53 (B) 298.17 1-ol 28(1S,2S)-2-(((5-chlorothiophen-2-yl)methyl)amino)cyclohexan-1-ol 0.91 (B)246.12 29 (1S,2S)-2-(((5-chlorothiazol-2-yl)methyl)amino)cyclohexan-1-ol0.77 (B) 247.12 30(1S,2S)-2-(((1-methyl-1H-pyrazol-3-yl)methyl)amino)cyclohexan- 0.52 (B)210.34 1-ol

Preparation of Compounds of Structure 2 Protected with a SilylProtective Group

Compounds of Structure 7 can be further protected at the hydroxy groupfollowing the procedures below

Intermediate 31:(1S,2S)—N-(2-(trifluoromethyl)benzyl)-2-((trimethylsilyl)oxy)cyclohexan-1-amine

To a solution of Intermediate 15 (556 mg, 2.03 mmol, 1 eq) and2,6-lutidine (0.479 mL, 4.07 mmol, 2 eq) in dry DCM (10 mL) at 0° C. isdropwise added trimethylsilyl trifluoromethanesulfonate 99% (0.558 mL,3.05 mmol, 1.5 eq). The mixture is stirred at 0° C. for 5 min and thenallowed arm to rt. The mixture is quenched with water and extractedtwice with DCM. The combined org. layers are dried using a phaseseparator and are then concentrated under reduced pressure. The crude isabsorbed on isolute and purified by FC CombiFlash (12 g RediSep column,0-100% EA in hept within 10 min) to give the title intermediate (545 mg)as a colourless oil.

LCMS (B): t_(R)=1.41 min; [M+H]+=346.23

Intermediate 32:(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-(2-(trifluoromethyl)benzyl)cyclohexan-1-amine

To a solution of Intermediate 15 (2000 mg, 7.32 mmol, 1 eq) and2,6-lutidine (1.7 mL, 14.6 mmol, 2 eq) in dry DCM (80 mL) at 0° C. isdropwise added tert-butyldimethylsilyl trifluoromethanesulphonate (2.52mL, 11 mmol, 1.5 eq). The mixture is stirred at 0° C. for 5 min and thenallowed to warm to rt. The mixture is quenched with water and extractedtwice with DCM. The combined org. layers are dried using a phaseseparator and are then concentrated under reduced pressure. The crude isabsorbed on isolute and purified by FC CombiFlash (40 g RediSep column,0-100% EA in hept within 10 min) to give the title intermediate as ayellowish oil.

LCMS (A): t_(R)=0.96 min; [M+H]+=388.27

The following intermediates are prepared in analogy:

t_(R) [min] MS Data Intermediate Compound (LC-MS) m/z [M + H]⁺ 33(1S,2S)-N-(2-chlorobenzyl)-2-((trimethylsilyl)oxy)cyclohexan-1- 1.37 (B)312.31 amine 34(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((3-(trifluoromethyl)pyridin-0.96 (A) 389.28 2-yl)methyl)cyclohexan-1-amine 35(1S,2S)-N-((4,6-dimethoxypyrimidin-5-yl)methyl)-2- 1.16 (B) 340.27((trimethylsilyl)oxy)cyclohexan-1-amine 36(1S,2S)-N-((4-methylpyrimidin-5-yl)methyl)-2- 0.98 (B) 294.29((trimethylsilyl)oxy)cyclohexan-1-amine 37 tert-butyl4-((((1S,2S)-2-((tert- 0.98 (A) 424.43butyldimethylsilyl)oxy)cyclohexyl)amino)methyl)-5-methyl-1H-imidazole-1-carboxylate 38(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((4-chloroisothiazol-5- 0.87(A) 361.22 yl)methyl)cyclohexan-1-amine 39(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((3-methylthiophen-2- 0.93(A) 340.30 yl)methyl)cyclohexan-1-amine 40(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((1-methyl-1H-pyrrol-2- 0.92(A) 323.37 yl)methyl)cyclohexan-1-amine 41(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((3-chlorothiophen-2- 0.94(A) 360.23 yl)methyl)cyclohexan-1-amine 42(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((4-methylthiazol-5- 0.84 (A)341.30 yl)methyl)cyclohexan-1-amine 43(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((1-methyl-1H-imidazol-2-0.79 (A) 324.36 yl)methyl)cyclohexan-1-amine 44(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((2-methylthiophen-3- 0.94(A) 340.31 yl)methyl)cyclohexan-1-amine 45(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-(2- 0.96 (A) 350.22methoxybenzyl)cyclohexan-1-amine 46(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-(2,6- 1.00 (A) 380.21dimethoxybenzyl)cyclohexan-1-amine 47(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((1-ethyl-1H-pyrazol-5- 0.85(A) 337.74 yl)methyl)cyclohexan-1-amine 48(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((1-isopropyl-1H-pyrazol-5-0.89 (A) 352.31 yl)methyl)cyclohexan-1-amine 49(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((1-(cyclopropylmethyl)- 0.90(A) 364.15 1H-pyrazol-5-yl)methyl)cyclohexan-1-amine 50(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((1,3-dimethyl-1H-pyrazol-0.85 (A) 338.02 5-yl)methyl)cyclohexan-1-amine 51(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-((1-methyl-1H-indol-2- 0.99(A) 373.33 yl)methyl)cyclohexan-1-amine 52(1S,2S)-2-((tert-butyldimethylsilyl)oxy)-N-(3- 0.95 (A) 353.96chlorobenzyl)cyclohexan-1-amine

Intermediate 53:(1S,2S)-2-(((4-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)cyclohexan-1-olStep 1: (4-(trifluoromethyl)pyrimidin-5-yl)methanol

4-(Trifluoromethyl)pyrimidine-5-carboxylic acid (1000 mg, 5.21 mmol, 1eq) is dissolved in THF (26 mL, 26 mmol, 5 eq) and cooled to −10° C.(dry ice bath). 4-Methylmorpholine (1.17 mL, 10.4 mmol, 2 eq) is addedat −15 to −10° C., followed by the addition of ethyl chloroformate (0.77mL, 7.81 mmol, 1.5 eq) at an internal temperature of −20 to −10° C. THF(10 mL) is added slowly, keeping the internal temperature below −10° C.to improve stirring. The mixture kept at −10° C. for 30 min. After 30min, sodium borohydride (761 mg, 19.5 mmol, 3 eq) is added at −10° C.and stirring at this temperature is continued for 5 min. Then, thedry-ice bath is exchanged by an ice-bath and the mixture is stirred at0° C. for 1 h. The reaction mixture is quenched with water (30 mL),acidified with 10% citric acid to pH 4-5, then extracted with n-butanol(3×). Org. layers are combined, dried over MgSO₄, filtered andevaporated to give a crude orange oil which is still containing somesalts. The mixture is suspended in DCM and salts are filtered off. Thefiltrate is concentrated and the residue is purified by FC CombiFlash(12 g RediSep column, 10-100% EA in hept). The intermediate alcohol isisolated as a yellow oil.

LCMS (A): t_(R)=0.49 min; [M+H]+=220.3

Step 2: 4-(trifluoromethyl)pyrimidine-5-carbaldehyde

Above alcohol (365 mg, 2.05 mmol, 1 eq) is dissolved in DCM (15 mL) andactivated manganese(IV) oxide, (3001 mg, 29.3 mmol, 14.32 eq) is addedat rt. The mixture is stirred at rt o/n. The mixture is filtered over aglass-fibre filter and the filtrate is evaporated to give the titlealdehyde as a yellow oil.

Step 3:(1S,2S)-2-(((4-(trifluoromethyl)pyrimidin-5-yl)methyl)amino)cyclohexan-1-ol

(1S,2S)-2-Aminocyclohexanol (150 mg, 1.26 mmol, 1 eq) and above aldehyde(245 mg, 1.39 mmol, 1.1 eq) are dissolved in DCM/MeOH 4/1 (5 mL) andsodium cyanoborohydride (100 mg, 1.52 mmol, 1.2 eq) is added portionwiseat rt. The mixture is stirred at rt for 3 h. The mixture is diluted withDCM and carefully quenched with water. The mixture is basified with 25%NH₄OH solution and the layers are separated (phase separator). Theorganic layer is concentrated and the crude is purified by FC(CombiFlash, 4 g RediSep column, 0-10% MeOH in EA) to give the titleintermediate as a yellow oil.

LCMS (A): t_(R)=0.46 min; [M+H]+=276.27

Intermediate 54:rac-N-((1R*,2R*)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3,4-difluoroanilineStep 1: rac-(1R*,2R*)-2-((3,4-difluorophenyl)amino)cyclohexan-1-ol

Cyclohexene oxide (0.258 mL, 2.5 mmol, 1 eq) and 3,4-difluoroaniline(391 mg, 3 mmol, 1.2 eq) are mixed with water (4 ml) and heated at 90°C. o/n. The mixture is diluted with water and EA and the org. phase isdried over MgSO₄ and concentrated. The product is purified by FC(hept/EA 4:1-1:1) to give the desired aminoalcohol as a brownish oil.

LCMS (A): t_(R)=0.71 min; [M+H]+=228.24

Step 2rac-N-((1R*,2R*)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3,4-difluoroaniline

To a solution of intermediate of step 1 (320 mg, 1.41 mmol, 1 eq) and2,6-lutidine (0.328 mL, 2.82 mmol, 2 eq) in DCM dry (14.1 ml) isdropwise added tert-butyldimethylsilyl trifluoromethanesulphonate (0.485mL, 2.11 mmol, 1.5 eq) at 0° C. for 5 min. The mixture is diluted with10 mL water. The layers are separated (phase separator) and the aq.phase is re-extracted twice with 5 mL DCM. The org. layer is evaporatedand dried at hv o/n. The crude is purified by FC (CombiFlash, 12 gRed-Sep column, 0-50% EA in hept) to give the desired intermediate as anorange oil.

LCMS (A): t_(R)=1.27 min; [M+H]+=342.00

Following compounds are prepared in analogy to Intermediate 54 steps 1and 2.

t_(R) [min] MS Data Intermediate Compound (LC-MS A) m/z [M + H]⁺  55rac-N-((1R*,2R*)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloroaniline1.30 340.17  56rac-N-((1R*,2R*)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3,5- 1.33374.12 dichloroaniline  57N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-methoxyaniline1.17 336.17  583-(((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)amino)-5- 1.27365.15 chlorobenzonitrile  59 3-bromo-5-(((1S,2S)-2-((tert- 1.27 408.94butyldimethylsilyl)oxy)cyclohexyl)amino)benzonitrile  60rac-3-(((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)amino)-5-1.26 345.2 methylbenzonitrile  613-(((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)amino)-5- 1.26361.1 methoxybenzonitrile  62rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloro-5-1.30 353.92 methylaniline  633-bromo-N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)aniline1.31 358.64  64rac-3-(((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)amino)benzonitrile1.24 331.17  65rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-5-chloro-2-1.32 354.13 methylaniline  66rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloro-4-1.29 358.12 fluoroaniline  67rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloro-4-1.32 408.09 (trifluoromethyl)aniline  68rac-3-bromo-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-4-1.28 402.06 fluoroaniline  69rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)benzo[d]thiazol-6-1.25 363.13 amine  70rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2- 1.23377.14 methylbenzo[d]thiazol-6-amine  71rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloro-5-1.31 408.13 (trifluoromethyl)aniline  72rac-3-bromo-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-5-1.33 420.01 chloroaniline  73rac-3,5-dibromo-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)aniline1.34 463.92  74rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3,4-dichloroaniline1.32 374.06  75rac-3-bromo-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-4-1.32 419.99 chloroaniline  76rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)aniline 1.12306.18  77N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)benzo[b]thiophen-6-1.2 362.04 amine  78N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloro-5- 1.29369.81 methoxyaniline  79N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-5-chloro-2-fluoroaniline1.31 357.91  80rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2,5- 1.25391.18 dimethylbenzo[d]thiazol-6-amine  81rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2- 1.29397.11 chlorobenzo[d]thiazol-6-amine  82rac-5-bromo-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2-1.31 400.1 methylaniline  83rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-4-chloroaniline1.27 340.07  84rac-3-(((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)amino)-5-1.24 349.18 fluorobenzonitrile  85rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-fluoroaniline1.26 324.21  86rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3- 1.29 374.2(trifluoromethyl)aniline  87rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3,5-difluoroaniline1.27 342.15  88rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-fluoro-5-1.25 353.95 methoxyaniline  89rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-fluoro-5-1.28 337.95 methylaniline  903-bromo-N-((1RS,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-5- 1.3401.8 fluoroaniline  91N-((1RS,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloro-5- 1.3358.18 fluoroaniline  92rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-methylaniline1.12 320.25  93rac-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2-methyl-1H-0.91 360.23 benzo[d]imidazol-6-amine  94N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2,3-difluoroaniline1.26 342.14  95N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-6-fluoro-3- 0.98420.18 methoxyquinoxalin-5-amine  96N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-chloroquinolin-2-1.01 405.14 amine  97N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)pyridin-2-amine0.87 307.12 129N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)naphthalen-2-amine1.28 356.13 130N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)naphthalen-1-amine1.29 356.13 131N-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-1,5-dimethyl-1H-0.88 324.17 pyrazol-3-amine 132 *rac-(1R,2R)-2-((tert-butyldimethylsilyl)oxy)-N-(3-chlorophenyl)cycloheptan-1.36 353.82 1-amine 133 *rac-(1R,2R)-2-((tert-butyldimethylsilyl)oxy)-N-(3,5- 1.39 388.20dichlorophenyl)cycloheptan-1-amine * prepared from cycloheptene oxide

Intermediate 98: Methyl(4aR,6R,7R,8R,8aR)-7-hydroxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate

To a solution of the intermediate 5a (120 mg 0.279 mmol, 1 eq) in DMF(2.4 ml) is added NaH (60% dispersion in mineral oil, 11.3 mg, 0.282mmol) at 0° C. The reaction mixture is stirred for 0.5 h at rt. Dimethylsulfate (0.029 ml, 0.307 mmol) is added and the reaction mixture isstirred for 1 hour at rt. The mixture is cooled and quenched with water,extracted twice with ethyl acetate. The combined org. layers are washedwith aq. sat. NaCl solution (10 ml), dried with MgSO4 and evaporated.The product is purified by CombiFlash, 24 g RediSep column, 0-100% ethylacetate in hexane. The product is isolated as a colourless solid. LCMS(A): t_(R)=0.88 min; [M+H]+=444.20.

Intermediate 99: Methyl(4aR,6R,7R,8R,8aR)-7-(2-(tert-butoxy)-2-oxoethoxy)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-8-carboxylate

To a solution of intermediate 98 (650 mg, 1.47 mmol, 1 eq) in DMF (15ml) is added at rt tert-butyl bromoacetate (409 mg, 2.05 mml) and NaH(60% dispersion in mineral oil, 78 mg, 2.05 mmol). The reaction mixtureis stirred for 2.5 h at rt. The mixture is cooled and quenched withwater, extracted twice with ethyl acetate. The combined org. layers arewashed with aq. sat. NaCl solution (10 ml), dried with MgSO4 andevaporated. The product is purified by CombiFlash, 24 g RediSep column,0-100% ethyl acetate in hexane. The product is isolated as a colourlesssolid. LCMS (A): t_(R)=1.05 min; [M+H]+=558.01.

Intermediate 100a:(4aR,6R,7R,8R,8aR)-7-(2-(tert-butoxy)-2-oxoethoxy)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-8-carboxylicacid

To a solution of intermediate 99 (673 mg, 1.21 mmol, 1 eq) in THF, MeOH,H₂O (21 ml, 3:2:1) is added at 0° C. LiOH (44 mg, 1.81 mmol) and themixture is stirred 1 h. Additional LiOH (44 mg, 1.81 mmol) is added andthe mixture is stirred for 0.5 h. 1N aq. HCl is added to maintain pH 4and the mixture is extracted twice with ethyl acetate. The combined org.layers are washed with aq. sat. NaCl solution (10 ml), dried with MgSO4and evaporated. The product is isolated as a colourless solid. LCMS (A):t_(R)=0.96 min; [M+H]+=543.99.

Intermediate 100b:(4aR,6R,7R,8R,8aR)-7-(2-(tert-butoxy)-2-oxoethoxy)-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylicacid

This compound is prepared in analogy to intermediate 100a from thecorresponding acid.

Intermediate 101: Tert-butyl2-(((4aR,6R,7R,8R,8aR)-6-(((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)(3,5-dichlorophenyl)carbamoyl)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)acetate

The compound is prepared from the intermediate 100a and intermediate 56according to the general procedure B.

LCMS (A): t_(R)=1.43 min; [M+H]+=899.17.

Intermediate 102: Tert-butyl2-(((2R,3R,4S,5R,6R)-2-((3,5-dichlorophenyl)((1S,2S)-2-hydroxycyclohexyl)carbamoyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetate

To a solution of intermediate 101 (450 mg, 0.50 mmol) in 1,4-dioxane (24ml) and water (12 ml) is added at 0° C. dropwise TFA (3.1 ml). Thereaction mixture is stirred at rt for 16 h. Sat aq. NaHCO₃ is added tomaintain pH 8 and the mixture is extracted twice with ethyl acetate. Thecombined org. layers are washed with aq. sat NaCl solution (10 ml),dried with MgSO4 and evaporated. The product is isolated as a yellowishoil. LCMS (A): t_(R)=1.10 min; [M+H]+=745.19.

The following intermediated are prepared in 2 steps procedure fromcorresponding starting materials in analogy to acid 6a.

t_(R) [min] MS Data Intermediate Compound (LC-MS A) m/z [M + H]⁺ 103a(4aR,6R,7R,8R,8aR)-8-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3- 0.89460.09 triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 103b methyl(4aR,6R,7R,8R,8aR)-8-(4-(3-chloro-4,5-difluorophenyl)- 0.91 460.061H-1,2,3-triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate 104a(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3- 0.90460.01 triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 104b(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3- 0.83445.96 triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 104c(4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5- 0.90 487.96difluorophenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 105a(4aR,6R,7R,8R,8aR)-8-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3- 0.90503.91 triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 105b(4aR,6R,7R,8R,8aR)-8-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3- 0.83491.85 triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 106a(4aR,6R,7R,8R,8aR)-8-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3- 0.87 487.92triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 106b(4aR,6R,7R,8R,8aR)-8-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3- 0.80 473.91triazol-1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 107(4aR,6R,7R,8R,8aR)-8-(4-(3-fluoro-2-methylphenyl)-1H-1,2,3- 0.83 421.91triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 108(4aR,6R,7R,8R,8aR)-8-(4-(5-fluoro-2-methoxyphenyl)-1H-1,2,3- 0.81 437.75triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 109(4aR,6R,7R,8R,8aR)-8-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3- 0.88 486.02triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 110(4aR,6R,7R,8R,8aR)-8-(4-(3,4-difluorophenyl)-1H-1,2,3-triazol-1- 0.81425.99 yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 111(4aR,6R,7R,8R,8aR)-8-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3- 0.83 421.97triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 112(4aR,6R,7R,8R,8aR)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3- 0.87440.12 triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 113(4aR,6R,7R,8R,8aR)-8-(4-(4,5-difluoro-2-methoxyphenyl)-1H- 0.85 456.091,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 114(4aR,6R,7R,8R,8aR)-8-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3- 0.89505.92 triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 115(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3- 0.89460.03 triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 116(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3- 0.86 441.86triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 117(4aR,6R,7R,8R,8aR)-8-(4-(3-fluoro-4-(trifluoromethyl)phenyl)-1H- 0.91476.09 1,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 118(4aR,6R,7R,8R,8aR)-8-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3- 0.82 433.02triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 119(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-2,5-difluorophenyl)-1H-1,2,3- 0.88460.06 triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 120(4aR,6R,7R,8R,8aR)-8-(4-(3,4-difluoro-5-methoxyphenyl)-1H- 0.86 456.081,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 121(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3-methoxyphenyl)-1H-1,2,3- 0.83 453.69triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 122(4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3-(trifluoromethoxy)phenyl)- 0.94508.00 1H-1,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 123(4aR,6R,7R,8R,8aR)-8-(4-(3-fluoro-5-methylphenyl)-1H-1,2,3- 0.83 422.00triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 124(4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(2- 0.80 461.08methylbenzo[d]thiazol-6-yl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 125(4aR,6R,7R,8R,8aR)-8-(4-(4-fluoronaphthalen-1-yl)-1H-1,2,3- 0.87 458.01triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 126a(4aR,6R,7R,8R,8aR)-8-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol- 0.73430.98 1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 126b(4aR,6R,7R,8R,8aR)-8-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol- 0.64416.90 1-yl)-7-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 127(4aR,6R,7R,8R,8aR)-8-(4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)- 0.84424.02 7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid 128(4aR,6R,7R,8R,8aR)-8-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)- 0.86469.54 7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid

B—Preparation of Examples General Procedure A: Amide Coupling with T3P

To a solution of acid component (1 eq) and amine intermediate (1.1 eq)in DMF (5 mL/mmol) is added DIPEA (1.5 eq) and T3P (50% solution in EA,1.5 eq) and the mixture is stirred at rt until complete conversion.After aqueous workup (EA/dil HCl) the products are purified as describedin the general methods.

General Procedure B: Amide Coupling with POCl₃/Pyridine

To a solution of acid component (1 eq) and amine intermediate (1.2 eq)in DCM (10 mL/mmol) at 0° C. is dropwise added phosphorus(V) oxychloride(1M solution in pyridine, 0.451 mL, 0.451 mmol, 1 eq) within 2-3 min.The mixture is stirred at 0° C. for 10 min and then allowed to slowlywarm to rt. After completion of the reaction, the mixture is quenchedwith 10% citric acid and extracted twice with EA. The org. layers arewashed with brine. The combined org. layers are dried over magnesiumsulfate, filtered and concentrated. The products are purified asdescribed in the general methods.

General Procedure C: Deprotection with Aq AcOH

The protected intermediate (acetal and/or silyl Pg) (1eq) is refluxed inAcOH/H₂O 1:1 (5 mL/mmol) until completion of reaction. The products arepurified as described in the general methods.

General Procedure D: Deprotection with CSA in MeOH

CSA (0.1 eq) is added to the isopropylidene protected intermediate (1eq) in MeOH (5 mL/mmol) and heated at reflux until completion ofreaction. The products are purified as described in the general methods.

General Procedure E: Acetate Deprotection with K₂CO₃ in MeOH

K₂CO₃ (0.1 eq) is added to the acetate protected intermediate (1 eq) inMeOH (5 mL/mmol) and stirred at rt until completion of reaction. Theproducts are purified as described in the general methods.

Compounds of Examples listed in Table 1 below are prepared by applyingeither one of the above-mentioned procedures A or B in the coupling withacids 1-9, 98-128 and amines 10-97, 129-133. The final compounds areobtained by deprotection using procedures C, D or E.

TABLE 1 t_(R) [min] MS Data Ex. Compound (LC-MS) m/z [M + H]⁺  1(2R,3R,4S,5R,6R)-N-benzyl-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-0.86 (A) 577.236-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  2(2R,3R,4S,5R,6R)-N-(3-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2- 0.90 (A)611.01hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  3(2R,3R,4S,5R,6R)-N-(3-ethynylbenzyl)-3,5-dihydroxy-N-((1S,2S)-2- 0.89(A) 601.22hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  4(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.89(A) 591.26(hydroxymethyl)-N-phenethyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  5(2R,3R,4S,5R,6R)-N-(4-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2- 0.90 (A)611.03hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  6(2R,3R,4S,5R,6R)-N-(2-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2- 0.90 (A)611.25hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  7(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.94(A) 645.28(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  8(2R,3R,4S,5R,6R)-N-((3-chloropyridin-4-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-0.76 (A) 612.222-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  9(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.85(A) 646.10(hydroxymethyl)-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 10 (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-0.84 (A) 646.09(hydroxymethyl)-N-((4-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 11 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.00(A) 659.32(hydroxymethyl)-3-methoxy-N-(2-(trifluoromethyl)benzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 12 (2R,3R,4S,5R,6R)-N-(2-chlorobenzyl)-5-hydroxy-N-((1S,2S)-2- 0.97 (A)625.28hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  13(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.89(A) 646.08(hydroxymethyl)-N-((3-(trifluoromethyl)pyridin-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 14 (2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-0.61 (A) 582.10(hydroxymethyl)-N-((2-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 15(2R,3R,4S,5R,6R)-N-((2-amino-4-chlorothiazol-5-yl)methyl)-3,5-dihydroxy-N-0.76 (A) 633.24((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  16(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.75(A) 568.28(hydroxymethyl)-N-(isoxazol-4-ylmethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  17(2R,3R,4S,5R,6R)-N-((5-chlorofuran-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-0.88 (A) 601.262-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  18(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.77(A) 584.28(hydroxymethyl)-N-(isothiazol-4-ylmethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  19(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.61(A) 582.15(hydroxymethyl)-N-((1-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 20(2R,3R,4S,5R,6R)-N-((2-bromothiazol-4-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-0.85 (A) 661.992-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  21(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.67(A) 669.36(hydroxymethyl)-N-((2-morpholiriothiazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 22 (2R,3R,4S,5R,6R)-N-((5-chlorothiophen-2-yl)methyl)-3,5-dihydroxy-N-0.91 (A) 617.23((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  23(2R,3R,4S,5R,6R)-N-((5-chlorothiazol-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-0.85 (A) 618.252-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  24(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.76(A) 582.09(hydroxymethyl)-N-((1-methyl-1H-pyrazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 25 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.95(A) 660.33(hydroxymethyl)-3-methoxy-N-((3-(trifluoromethyl)pyridin-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  26(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.92 (A)660.36(hydroxymethyl)-3-methoxy-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  27(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.84(A) 647.37(hydroxymethyl)-N-((4-(trifluoromethyl)pyrimidin-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 28(2R,3R,4S,5R,6R)-N-((4,6-dimethoxypyrimidin-5-yl)methyl)-3,5-dihydroxy-N-0.82 (A) 639.4((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  29(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.72(A) 593.37(hydroxymethyl)-N-((4-methylpyrimidin-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 30 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.6(A)8 595.38(hydroxymethyl)-3-methoxy-N-((5-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  31(2R,3R,4S,5R,6R)-N-((4-chloroisothiazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-0.88 (A) 632.302-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 32 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.81(A) 595.18(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-pyrazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide[1,3-di-deoxy-2-O-methyl-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-((1-methyl-1H-pyrazol-5-yl)methyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide]  33(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.95 (A)611.36(hydroxymethyl)-3-methoxy-N-((3-methylthiophen-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 34 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.91(A) 594.38(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-pyrrol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide[1,3-di-deoxy-2-O-methyl-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-((1-methyl-1H-pyrrol-2-yl)methyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide]  35(2R,3R,4S,5R,6R)-N-((3-chlorothiophen-2-yl)methyl)-5-hydroxy-N-((1S,2S)-0.96 (A) 631.312-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 36 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.80(A) 612.36(hydroxymethyl)-3-methoxy-N-((4-methylthiazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 37 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.68(A) 595.18(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  38(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.96 (A)611.37(hydroxymethyl)-3-methoxy-N-((2-methylthiophen-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 39 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.95(A) 621.18(hydroxymethyl)-3-methoxy-N-(2-methoxybenzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  40(2R,3R,4S,5R,6R)-N-(2,6-dimethoxybenzyl)-5-hydroxy-N-((1S,2S)-2- 0.96(A) 651.19hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  41(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.63(A) 581.24(hydroxymethyl)-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 42(2R,3R,4S,5R,6R)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-0.69 (A) 623.141H-imidazol-2-yl)methyl)carbamoyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate 43(2R,3R,4S,5R,6R)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-0.80 (A) 623.141H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate 44(2R,3R,4S,5R,6R)-N-((1-ethyl-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-0.84 (A) 609.302-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 45 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.86(A) 623.29(hydroxymethyl)-N-((1-isopropyl-1H-pyrazol-5-yl)methyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  46(2R,3R,4S,5R,6R)-N-((1-(cyclopropylmethyl)-1H-pyrazol-5-yl)methyl)-5-0.88 (A) 635.29hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  47(2R,3R,4S,5R,6R)-N-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-0.79 (A) 609.27((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 48 (2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.99(A) 644.29(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-indol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 49(2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-0.77 (A) 605.16 2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate 50(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-0.83 (A) 639.14hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate 51(2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-0.81 (A) 619.22hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate 52(2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-0.74 (A) 587.18 (((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate 53 (2R,3R,4S,5R,6R)-N-(3-chlorobenzyl)-5-hydroxy-N-((1S,2S)-2- 0.98 (A)624.96hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  54(2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-1.00 (A) 683.20 hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate[1,3-di-deoxy-2-O-acetyl-3-[4-(4-methyl-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-(3-trifluoromethylphenyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide]  55(2R,3R,4S,5R,6R)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2- 0.99 (A)687.02 (trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate 56 (2R,3R,4S,5R,6R)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2- 0.96(A) 612.99hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide[1,3-di-deoxy-2-O-methyl-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-(3,4-difluorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide] Ref.(2R,3R,4S,5R,6R)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1R,2R)-2- 0.92 (A)612.99 Ex. 57hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  58(2R,3R,4S,5R,6R)-N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2- 0.97 (A)611.01hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide[1,3-di-deoxy-2-O-methyl-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-(3-chlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide]Ref. (2R,3R,4S,5R,6R)-N-(3-chlorophenyl)-5-hydroxy-N-((1R,2R)-2- 0.94(A) 611.02 Ex. 59hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  60(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.01 (A)645.01hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide[1,3-di-deoxy-2-O-methyl-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-(3,5-dichlorophenyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide] Ref.(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1R,2R)-2- 0.98 (A)644.92 Ex. 61hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  62(2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-1.10 (D) 651.50(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate  63(2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-1.13 (D) 669.502-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate  64(2R,3R,4S,5R,6R)-N-((6-fluoro-3-methoxyquinoxalin-5-yl)methyl)-5-hydroxy-1.11 (E) 691.37N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 65(2R,3R,4S,5R,6R)-N-((3-chloroquinolin-2-yl)methyl)-5-hydroxy-N-((1S,2S)-2-1.20 (D) 676.32hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  66(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-1.13 (D) 661.263,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide  67(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-1.14 (D) 661.503,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide  68(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-1.20 (E) 703.39 hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate  69(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-1.14 (D) 706.603,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide  70(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-1.11 (D) 688.36dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide  71(2R,3R,4S,5R,6R)-4-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl)-3,5-0.96 (E) 632.28dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide  72(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3-fluorophenyl)-1H-1,2,3-1.16 (E) 610.18triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  73(2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-1.03 (E) 571.30((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)tetrahydro-2H-pyran-2-carboxamide  74(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluorophenyl)-1H-1.06 (E) 600.271,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide [1,3-di-deoxy-2-O-methyl-3-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-(3-chloro-5-cyanophenyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide]  75(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-2- 1.09 (E)614.28 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  76(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(5-fluoro-2- 1.09 (E)630.20 methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  77(2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(3-fluorophenyl)-1H-1.08 (E) 644.511,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  78(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-1.21 (E) 628.05triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  79(2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-1.08 (E) 589.24N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)tetrahydro-2H-pyran-2-carboxamide [1,3-di-deoxy-2-O-methyl-3-[4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl]-(N-(3-methoxyphenyl)-N-((1S,2S)-2-hydroxycyclohexyl))-β-D-galacto-pyranose-1-carboxamide]  80(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3,5-difluorophenyl)-1H-1.11 (E) 618.281,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  81(2R,3R,4S,5R,6R)-N-(3-cyano-5-methylphenyl)-4-(4-(3,5-difluorophenyl)-1H-1.09 (E) 598.301,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  82(2R,3R,4S,5R,6R)-N-(3-cyano-5-methoxyphenyl)-4-(4-(3,5-difluorophenyl)-1.08 (E) 614.301H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  83(2R,3R,4S,5R,6R)-N-(3-chloro-5-methylphenyl)-4-(4-(3,5-difluorophenyl)-1H-1.19 (E) 607.301,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  84(2R,3R,4S,5R,6R)-N-(3-bromophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-1.15 (E) 639.00triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  85(2R,3R,4S,5R,6R)-N-(3-chlorophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-1.13 (E) 593.20triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  86(2R,3R,4S,5R,6R)-N-(3-cyanophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-1.04 (D) 584.40triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide  87(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.24 (E)648.20 hydroxycyclohexyl)-6-(hydroxymethyl)-3-(methoxy-d₃)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 88 (2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-1.11 (E) 636.10hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  89(2R,3R,4S,5R,6R)-N-(5-chloro-2-methylphenyl)-5-hydroxy-N-((1S,2S)-2-1.22 (E) 625.33hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  90(2R,3R,4S,5R,6R)-N-(3-chloro-4-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-1.19 (E) 629.26hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  91(2R,3R,4S,5R,6R)-N-(3-chloro-4-(trifluoromethyl)phenyl)-5-hydroxy-N-1.26 (D) 679.22((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 92 (2R,3R,4S,5R,6R)-N-(3-bromo-4-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-1.19 (E) 675.11hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  93(2R,3R,4S,5R,6R)-N-(benzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2- 1.05(D) 634.33hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  94(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.09 (E)648.27(hydroxymethyl)-3-methoxy-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 95 (2R,3R,4S,5R,6R)-N-(3-chloro-5-(trifluoromethyl)phenyl)-5-hydroxy-N-1.26 (E) 679.31((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 96 (2R,3R,4S,5R,6R)-N-(3-bromo-5-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-1.25 (E) 690.67hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  97(2R,3R,4S,5R,6R)-N-(3,5-dibromophenyl)-5-hydroxy-N-((1S,2S)-2- 1.27 (E)735.05hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  98(2R,3R,4S,5R,6R)-N-(3,4-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.23 (E)645.79hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide  99(2R,3R,4S,5R,6R)-N-(3-bromo-4-chlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.24(E) 691.16hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 100(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.04 (E)577.20(hydroxymethyl)-3-methoxy-N-phenyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 101(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.12 (E)607.31(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 102(2R,3R,4S,5R,6R)-N-(benzo[b]thiophen-6-yl)-5-hydroxy-N-((1S,2S)-2- 1.18(E) 633.25hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 103(2R,3R,4S,5R,6R)-N-(3-bromophenyl)-5-hydroxy-N-((1S,2S)-2- 1.17 (D)657.14hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 104(2R,3R,4S,5R,6R)-N-(3-chloro-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-1.19 (E) 641.20hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 105(2R,3R,4S,5R,6R)-N-(5-chloro-2-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-1.17 (E) 629.27hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 106(2R,3R,4S,5R,6R)-N-(2,5-dimethylbenzo[d]thiazol-6-yl)-5-hydroxy-N- 1.10(E) 662.24((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide107(2R,3R,4S,5R,6R)-N-(2-chlorobenzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2-1.18 (E) 668.10hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 108(2R,3R,4S,5R,6R)-N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-1.10 (E) 632.31hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 109(2R,3R,4S,5R,6R)-N-(5-bromo-2-methylphenyl)-5-hydroxy-N-((1S,2S)-2- 1.23(E) 671.15hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 111(2R,3R,4S,5R,6R)-N-(4-chlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.18 (D)611.40hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 112(2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2- 1.15(E) 681.00hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 113(2R,3R,4S,5R,6R)-N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.10(E) 620.23hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 114(2R,3R,4S,5R,6R)-N-(3-fluorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.11 (E)595.20hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 115(2R,3R,4S,5R,6R)-N-(3-cyanophenyl)-5-hydroxy-N-((1S,2S)-2- 1.07 (E)602.24hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 116(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.19 (E)645.20(hydroxymethyl)-3-methoxy-N-(3-(trifluoromethyl)phenyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide117 (2R,3R,4S,5R,6R)-N-(3,5-difluorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.15(D) 613.40hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 118(2R,3R,4S,5R,6R)-N-(3-fluoro-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-1.16 (D) 625.40hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 119(2R,3R,4S,5R,6R)-N-(3-fluoro-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-1.17 (E) 609.28hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 120(2R,3R,4S,5R,6R)-N-(3-bromo-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.21(D) 675.40hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 121(2R,3R,4S,5R,6R)-N-(3-chloro-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-1.20 (D) 629.40hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 122(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.15 (E)591.20(hydroxymethyl)-3-methoxy-N-(m-tolyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 123(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.72 (D)631.40(hydroxymethyl)-3-methoxy-N-(2-methyl-1H-benzo[d]imidazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 129(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.28 (E) 663.18(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 130(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.19 (D) 629.29(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 131(2R,3R,4S,5R,6R)-N-(benzo[d]thiazol-6-yl)-4-(4-(3-chloro-4,5- 1.09 (E)650.12 difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 132(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.19 (E) 653.29(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 133(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3-chloro-5- 1.17 (E)634.83 fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 134(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.17 (E) 611.27(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 135(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.13 (E) 618.40cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 136(2R,3R,4S,5R,6R)-N-(3-bromo-5-fluorophenyl)-4-(4-(3-chloro-5- 1.22 (E)673.22 fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 137(2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(3-chloro-5- 1.18 (E)680.16 fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 138(2R,3R,4S,5R,6R)-N-(3-bromophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1.21 (E) 655.261,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 139(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.27 (E) 643.20(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 140(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.14 (D) 614.29cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 141(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.14 (D) 630.32cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 142(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.10 (D) 600.25cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 143(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.20 (E) 609.20chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 144(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.28 (D) 689.18(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 145(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.19 (D) 680.22chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 146(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.16 (E) 659.47cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 147(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.24 (D) 673.30chloro-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 148(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.11 (D) 646.16cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 149(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.21 (D) 655.26chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 150(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.15 (E) 676.18cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 151(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.29 (E) 707.06(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 152(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.20 (D) 675.11(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 153(2R,3R,4S,5R,6R)-N-(benzo[d]thiazol-5-yl)-4-(4-(4-bromo-3,5- 1.10 (E)695.90 difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 154(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.21 (E) 698.24(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 155(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.16 (E) 681.66(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 156(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.29 (E) 662.30(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 157(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.19 (D) 652.98(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 158(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1.26 (D) 642.431H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 159(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3,5-difluoro-4- 1.16(E) 632.22 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 160(2R,3R,4S,5R,6R)-N-(3-bromo-5-fluorophenyl)-4-(4-(3,5-difluoro-4- 1.23(D) 671.40 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 161(2R,3R,4S,5R,6R)-N-(3-cyano-5-fluorophenyl)-4-(4-(3,5-difluoro-4- 1.12(E) 616.36 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 162(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3,4-difluorophenyl)-1H-1,2,3-1.19 (D) 627.30triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 163(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.25 (E) 689.10(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 164(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.16 (D) 657.21(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 165(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-1.16 (E) 680.27chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 166(2R,3R,4S,5R,6R)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.34 (E) 679.13(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 167(2R,3R,4S,5R,6R)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.24 (D) 646.27(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 168(2R,3R,4S,5R,6R)-N-(benzo[d]thiazol-6-yl)-4-(4-(3,4-dichloro-5- 1.14 (E)667.44 fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 169(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3,4-dichloro-5- 1.24(E) 669.18 fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 170(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-4- 1.11 (E)614.32 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 171(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(2,3-difluoro-4- 1.14(E) 632.25 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 1722-(((2R,3R,4S,5R,6R)-2-((3-chloro-5-cyanophenyl)((1S,2S)-2- 1.00 (D)677.30hydroxycyclohexyl)carbamoyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)aceticacid 173(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(2,3-difluoro-4- 1.03(E) 745.43 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)tetrahydro-2H-pyran-2-carboxamide 174(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(4,5-difluoro-2- 1.13(E) 648.40 methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 175(2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.19 (E) 698.20(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 176(2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.15 (E) 682.27(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 177(2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.28 (E) 706.84(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 178(2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.18 (E) 652.26(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 179(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.24 (E) 645.06(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 180(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3-fluoro-4- 1.28 (E)677.80(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 181(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(4-cyano-3- 1.07 (D)625.33 fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 182(2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-1.18 (E) 653.02(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 183(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3,4-difluoro-5- 1.21 (E)657.90 methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 184(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-N-1.11 (E) 646.90(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 185(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-(trifluoromethoxy)phenyl)-1H-1,2,3-1.26 (D) 700.30triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 186(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1.20 (E) 651.881,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 187(2R,3R,4S,5R,6R)-N-(3-cyano-5-fluorophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1.16 (E) 634.331,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 188(2R,3R,4S,5R,6R)-N-(3-cyano-5-methoxyphenyl)-4-(4-(3,4-dichlorophenyl)-1.16 (D) 646.931H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 189(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-1.30 (D) 661.30triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 190(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-5- 0.92 (D)614.40 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 191(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.11 (E)664.00 hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(2-methylbenzo[d]thiazol-6-yl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 192(2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(4-fluoronaphthalen-1-yl)-1H-1.25 (E) 661.001,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 193(2R,3R,4S,5R,6R)-4-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl)-N-(2,3-0.97 (E) 600.10difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 194(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.01 (E)578.20(hydroxymethyl)-3-methoxy-N-(pyridin-2-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 197(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 1.00 (A)627.15(hydroxymethyl)-3-methoxy-N-(naphthalen-2-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 198(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6- 0.99 (A)627.14(hydroxymethyl)-3-methoxy-N-(naphthalen-1-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 199(2R,3R,4S,5R,6R)-N-(1,5-dimethyl-1H-pyrazol-3-yl)-5-hydroxy-N-((1S,2S)-2-0.88 (A) 595.14hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide 200(2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(3-fluoro-4- 0.96 (A)657.91 methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 201(2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(4-chlorophenyl)-1H-0.92 (A) 616.021,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 202(2R,3R,4S,5R,6R)-4-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-0.95 (A) 661.95cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 205(2R,3R,4S,5R,6R)-4-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-0.91 (A) 620.99cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 206(2R,3R,4S,5R,6R)-4-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-0.91 (A) 605.00cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide 207(2R,3R,4S,5R,6R)-N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.00 (A)625.08 hydroxycycloheptyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide208 (2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2- 1.04(A) 659.00 hydroxycycloheptyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide

Example 195:2-(((2R,3R,4S,5R,6R)-2-((3,5-dichlorophenyl)((1S,2S)-2-hydroxycyclohexyl)carbamoyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)aceticacid

To a solution of intermediate 102 (373 mg, 0.5 mol, 1 eq) in DCM (3 ml)is added at rt 2M TFA (1.20 ml) and the reaction mixture is stirred atrt for 3 h. The solvent is evaporated. The product is isolated as a TFAsalt. LCMS (A): t_(R)=0.90 nun; [M+H]+=689.18.

Example 196:(2R,3R,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-(1S,2S)-2-hydroxycyclohexyl-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide

To a solution of example 195 (54 mg, 0.067 mmol, 1 eq) in THF (3 ml) isadded at 0° C. 2M solution of BH₃.Me₂S in THF (0.14 ml, 4.2 eq) and thereaction mixture is stirred at rt for 24 h. MeOH (1 ml) and aq. satNH₄Cl solution (15 ml) is added and the mixture is extracted twice withethyl acetate. The combined org. layers are washed with aq. sat NaClsolution (10 ml) are evaporated. The product is purified by LC-MS (I).The product is isolated as a colourless solid. LCMS (A): t_(R)=0.90 min;[M+H]+=689.17.

Example 124:(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide

To a solution of example 195 (50 mg, 0.049 mmol, 1 eq) in DMF (1 ml) isadded at rt HATU (0.040 ml, 2 eq), morpholine (9 μl, 2 eq) and DIPEA (42μl, 5 eq) and the reaction mixture is stirred at rt for 0.5 h. Thereaction mixture is purified by LC-MS (I). The product is isolated as acolourless solid. LCMS (A): t_(R)=0.95 min; [M+H]+=757.99.

Following compounds are prepared in analogy to example 124 from theexample 195 and the corresponding amine.

Example 125:(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-((S)-3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide

LCMS (A): t_(R)=0.86 min; [M+H]+=758.19.

Example 126:(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-((R)-3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide

LCMS (A): t_(R)=0.86 min; [M+H]+=758.18.

Example 127:(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-(4-hydroxypiperidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide

Step1:(2R,3R,4S,5R,6R)-3-(2-(4-((tert-butyldimethylsilyl)oxy)piperidin-1-yl)-2-oxoethoxy)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamideis prepared from example 195 and4-((tert-butyldimethylsilyl)oxy)piperidine according to the proceduredescribed for example 124.

LCMS (A): t_(R)=1.23 min; [M+H]+=886.36.

Step 2: To the solution of the silyl ether described above (28 mg, 0.032mmol) in dioxan (3 ml) and water (1.45 ml) is added TFA (0.4 ml) and thereaction mixture is stirred at rt for 1.5 h. Ethyl acetate (10 ml) andaq. sat. NaHCO₃ solution (15 ml) is added to maintain the pH 8, thewater phase is separated and extracted twice with ethyl acetate. Thecombined org. layers are evaporated. The product is purified by LC-MS(I). The product is isolated as a colourless solid.

LCMS (A): t_(R)=0.88 min; [M+H]+=772.17.

Example 128:(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-3-(2-(3-hydroxyazetidin-1-yl)-2-oxoethoxy)-N-((1S,2S)-2-hydroxycyclohexyl-hydroxymethl)-4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide

This compound is prepared in 2 steps procedure in analogy to example127. LCMS (A): t_(R)=0.85 min; [M+H]+=744.09.

Example 203:(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(3,5-difluoro-4-morpholinophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide

Step 1: To a solution of the intermediate 6a ((0.100 mg, 0.226 mmol, 1eq), K2CO3 (0.156 mg, 1.13 mmol) in DMSO (4 ml) is added at rtmorpholine (0.100 ml, 1.13 mmol) and the reaction mixture is stirred at130° C. for 40 h. Morpholine (0.100 ml) is added and mixture is stirredfor 5 days. Ethyl acetate and aq. sat. NaH4Cl solution is added tomaintain the pH 6-7, the water phase is separated and extracted twicewith ethyl acetate. The combined org. layers are evaporated. The productis purified by LC-MS (I). The product is isolated as a colourless solid.LCMS (A): t_(R)=0.86 min; [M+H]+=511.03.

Step 2: The aide coupling of the acid from step 1 with the amine 56 isperformed according to the procedure B.

LCMS (A): t_(R)=1.42 min; [M+H]+=866.09.

Step 3: The product from step 2 is deprotected according to theprocedure described for example 127, step 2.

LCMS (A): t_(R)=1.00 min; [M+H]+=712.03.

Example 204:(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-((3-hydroxypropyl)amino)phenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide

Example 204 is prepared in analogy to example 203 using azetidineinstead of morpholine in step 1.

LCMS (A): t_(R)=0.93 min; [M+H]+=700.01.

II. Biological Assays Evaluation of Compound Inhibitory Activity (IC₅₀)

The inhibitory activity of compounds is determined in competitivebinding assays. This spectrophotometric assay measures the binding ofbiotinylated human Gal-3 (hGal-3) or human Gal-1 (hGAl-1), respectively,to a microplate-adsorbed glycoprotein, asialofetuin (ASF) (Proc NatlAcad Sci USA. 2013 Mar. 26; 110(13):5052-7.). Alternatively, andpreferably, a human Gal-1 version in which all six cysteines aresubstituted by serines may be used.

Briefly, compounds are serially diluted in DMSO (working dilutions).ASF-coated 384 well pates are supplemented with 22.8 μL/well ofbiotinylated hGal-3 or hGal-1 in assay buffer (i.e. 300-1000 ng/mLbiotinylated hGal-3 or hGal-1) to which 1.2 μL of compound workingdilutions are added and mixed.

Plates are incubated for 3 hours at 4° C. then washed with cold assaybuffer (3×50 uL), incubated for 1 hour with 25 μL/well of astreptavidin-peroxidases solution (diluted in assay buffer to 80 ng/mL)at 4° C., followed by further washing steps with assay buffer (3×50 uL).Finally, 25 μL/well of ABTS substrate is added. OD (410 nm) is recordedafter 30 to 45 min and IC₅₀ values are calculated.

The calculated IC₅₀ values may fluctuate depending on the daily assayperformance. Fluctuations of this kind are known to those skilled in theart. IC₅₀ values from several measurements are given as mean values.

TABLE 2 Activity on hGal-3 (IC₅₀ in μM): Gal-3 IC₅₀ Gal-3 IC₅₀ Gal-3IC₅₀ Gal-3 IC₅₀ Example [μM] Example [μM] Example [μM] Example [μM]  10.154  2 0.301  3 0.471  4 0.677  5 0.174  6 0.071  7 0.057  8 0.169  90.147  10 0.122  11 0.055  12 0.052  13 0.255  14 0.564  15 0.419  160.476  17 0.281  18 0.179  19 0.403  20 0.352  21 0.112  22 0.167  230.403  24 0.294  25 0.280  26 0.159  27 0.264  28 0.165  29 0.232  300.575  31 0.311  32 0.122  33 0.127  34 0.069  35 0.210  36 0.231  370.337  38 0.207  39 0.224  40 0.199  41 0.464  42 0.212  43 0.076  440.179  45 0.421  46 0.160  47 0.151  48 0.344  49 0.129  50 0.053  510.058  52 0.191  53 0.868  54 0.020  55 0.031  56 0.042 Ref. Ex. 57 1.37 58 0.021 Ref. Ex. 59 0.679  60 0.016 Ref. Ex. 61 0.511  62 0.141  630.138  64 0.123  65 0.196  66 0.095  67 0.042  68 0.044  69 0.084  700.090  71 0.143  72 0.031  73 0.069  74 0.044  75 0.050  76 0.042  770.037  78 0.026  79 0.062  80 0.025  81 0.073  82 0.017  83 0.026  840.025  85 0.035  86 0.111  87 0.007  88 0.013  89 0.010  90 0.026  910.147  92 0.018  93 0.020  94 0.031  95 0.016  96 0.014  97 0.013  980.033  99 0.032 100 0.073 101 0.036 102 0.043 103 0.025 104 0.019 1050.014 106 0.056 107 0.317 108 0.024 109 0.017 111 0.158 112 0.008 1130.018 114 0.049 115 0.025 116 0.026 117 0.038 118 0.026 119 0.030 1200.021 121 0.019 122 0.043 123 0.085 124 0.012 125 0.009 126 0.016 1270.012 128 0.013 129 0.032 130 0.053 131 0.034 132 0.013 133 0.022 1340.063 135 0.052 136 0.025 137 0.024 138 0.043 139 0.027 140 0.033 1410.056 142 0.077 143 0.024 144 0.061 145 0.018 146 0.050 147 0.071 1480.081 149 0.085 150 0.062 151 0.037 152 0.062 153 0.025 154 0.023 1550.024 156 0.014 157 0.019 158 0.015 159 0.012 160 0.011 161 0.025 1620.032 163 0.018 164 0.058 165 0.034 166 0.022 167 0.064 168 0.025 1690.014 170 0.018 171 0.012 172 0.011 173 0.009 174 0.040 175 0.013 1760.015 177 0.013 178 0.026 179 0.010 180 0.011 181 0.029 182 0.035 1830.009 184 0.029 185 0.232 186 0.017 187 0.037 188 0.044 189 0.011 1900.017 191 0.041 192 0.021 193 0.143 194 0.011 195 0.009 196 0.021 1970.097 198 0.117 199 0.321 200 0.008 201 0.020 202 0.021 203 0.024 2040.021 205 0.087 206 0.126 207 0.049 208 0.062

TABLE 3 Activity on hGal-1 (IC₅₀ in μM): Gal-1 IC₅₀ Gal-1 IC₅₀ Gal-1IC₅₀ Gal-1 IC₅₀ Example [μM] Example [μM] Example [μM] Example [μM]  16.495  2 22.8  3 >100  4 >100  5 18.2  6 1.920  7 1.235  8 2.49  9 1.64 10 1.69  11 0.497  12 0.497  13 7.25  14 40.6  15 3.181  16 28.3  1723.1  18 11.6  19 37.6  20 11.7  21 10.7  22 86.6  23 22.7  24 25.9  254.92  26 0.338  27 3.20  28 3.97  29 4.405  30 10.4  31 1.48  32 0.905 33 0.962  34 0.863  35 1.63  36 1.03  37 5.77  38 1.68  39 2.96  404.67  41 12.350  42 34.5  43 2.67  44 0.974  45 1.43  46 0.497  47 1.04 48 2.24  49 1.94  50 7.58  51 11.2  52 1.60  53 10.8  54 2.66  55 0.828 56 0.417 Ref. Ex. 57 13.2  58 0.729 Ref. Ex. 59 6.65  60 0.665 Ref. Ex.61 6.41  62 0.939  63 1.020  64 0.980  65 6.770  66 0.534  67 0.610  681.170  69 2.570  70 0.615  71 1.310  72 0.058  73 1.545  74 0.161  750.259  76 0.901  77 0.140  78 0.192  79 2.110  80 0.383  81 1.320  821.160  83 2.320  84 1.900  85 1.690  86 1.850  87 0.173  88 0.157  890.076  90 0.358  91 1.540  92 0.340  93 0.163  94 0.254  95 0.398  960.403  97 0.266  98 0.169  99 0.377 100 18.630 101 0.800 102 1.240 1030.238 104 1.185 105 0.136 106 0.143 107 1.200 108 1.575 109 0.100 1114.220 112 0.150 113 0.520 114 2.010 115 1.000 116 1.950 117 0.978 1181.480 119 1.830 120 0.422 121 0.449 122 4.750 123 5.880 124 0.226 1250.134 126 0.134 127 0.181 128 0.177 129 0.141 130 0.924 131 0.224 1320.140 133 0.184 134 0.761 135 0.270 136 0.323 137 0.318 138 0.935 1390.860 140 0.671 141 1.560 142 1.670 143 1.410 144 0.726 145 0.218 1460.751 147 0.530 148 0.343 149 0.707 150 0.671 151 1.130 152 3.140 1531.079 154 0.957 155 1.505 156 1.380 157 0.709 158 0.798 159 0.528 1601.765 161 2.170 162 0.134 163 1.275 164 1.940 165 0.792 166 1.340 1671.240 168 0.672 169 0.333 170 0.569 171 0.238 172 0.421 173 0.5089 1740.750 175 0.386 176 0.682 177 0.852 178 0.123 179 0.591 180 1.200 1810.618 182 0.267 183 0.516 184 0.282 185 1.370 186 0.210 187 0.359 1881.120 189 0.257 190 0.239 191 1.140 192 1.140 193 0.605 194 2.740 1950.096 196 0.161 197 6.830 198 >100 199 18.000 200 0.158 201 0.242 2020.341 203 0.678 204 0.273 205 1.820 206 1.340 207 1.790 208 0.586

1. A compound of formula (I)

wherein n represents the integer 1 or 2; Ar¹ represents aryl which ismono-, di-, tri-, tetra-, or penta-substituted, wherein the substituentsare independently selected from halogen; methyl; cyano; methoxy;trifluoromethyl; trifluoromethoxy; and NR^(N11)R^(N12) wherein R^(N11)represents hydrogen and R^(N12) represents hydroxy-C₂₋₃-alkyl, orR^(N11) and R^(N12) together with the nitrogen atom to which they areattached form a 4- to 6-membered heterocyclyl selected frommorpholin-4-yl, azetidine-1-yl, pyrrolidine-1-yl, and piperidine-1-yl,wherein said 4- to 6-membered heterocyclyl is unsubstituted ormono-substituted with hydroxy; 5- or 6-membered heteroaryl, wherein said5- or 6-membered heteroaryl independently is unsubstituted, mono- ordi-substituted, wherein the substituents are independently selected fromhalogen, methyl, cyano, and methoxy; or 9- or 10-membered heteroaryl,wherein said 9- or 10-membered heteroaryl independently isunsubstituted, or mono-substituted with methyl; R¹ represents hydroxy;C₁₋₃-alkoxy; O—CO—C₁₋₃-alkyl; —O—CH₂—CH₂—OH; or —O—CH₂—CO—R^(1X) whereinR^(1X) represents -hydroxy; morpholin-4-yl; or —NR^(N21)R^(N22), whereinR^(N21) and R^(N22) together with the nitrogen atom to which they areattached form a 4- to 6-membered heterocyclyl selected fromazetidine-1-yl, pyrrolidine-1-yl, and piperidine-1-yl, wherein said 4-to 6-membered heterocyclyl is mono-substituted with hydroxy; Lrepresents a direct bond, methylene, or ethylene; and Ar² representsphenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or6-membered heteroaryl independently is unsubstituted, or mono-, di- ortri-substituted; wherein the substituents independently are selectedfrom C₁₋₆-alkyl, C₃₋₆-cycloalkyl, —CH₂—C₃₋₆-cycloalkyl,C₁₋₃-fluoroalkyl, C₁₋₃-fluoroalkoxy, C₁₋₃-alkoxy, halogen,morpholine-4-yl, amino, ethynyl and cyano; 9-membered bicyclicheteroaryl or 10-membered bicyclic heteroaryl, wherein said 9- or10-membered bicyclic heteroaryl independently is unsubstituted, mono- ordi-substituted, wherein the substituents independently are selected frommethyl, methoxy, and halogen; or naphthyl; or a pharmaceuticallyacceptable salt thereof.
 2. A compound according to claim 1; wherein Ar¹represents a phenyl which is mono-, di- or tri-substituted, wherein thesubstituents are independently selected from halogen, methyl, cyano, andmethoxy; wherein at least one of said substituents is attached in ameta- or in para-position of said phenyl; or a pharmaceuticallyacceptable salt thereof.
 3. A compound according to claim 1; wherein Ar¹represents a phenyl group of the structure

wherein R^(m2) represents halogen; and R^(p) represents hydrogen,halogen, methyl, cyano, or methoxy; or a pharmaceutically acceptablesalt thereof.
 4. A compound according to claim 1; wherein R¹ representsmethoxy; or a pharmaceutically acceptable salt thereof.
 5. A compoundaccording to claim 1; wherein L represents a direct bond; or apharmaceutically acceptable salt thereof.
 6. A compound according toclaim 1; wherein Ar² represents phenyl which is unsubstituted, mono-, ordi-substituted wherein the substituents independently are selected fromC₁₋₄-alkyl, C₁₋₃-fluoroalkyl, C₁₋₃-alkoxy, halogen, ethynyl, and cyano;or 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroarylindependently is unsubstituted, mono-, or di-substituted wherein thesubstituents independently are selected from C₁₋₄-alkyl,—CH₂—C₃₋₆-cycloalkyl, C₁₋₃-fluoroalkyl, C₁₋₃-alkoxy, halogen,morpholine-4-yl, and amino; or a pharmaceutically acceptable saltthereof.
 7. A compound according to claim 1; wherein Ar² representsphenyl which is mono-, or di-substituted wherein the substituentsindependently are selected from C₁₋₃ fluoroalkyl, and halogen; or 5- or6-membered heteroaryl, wherein said 5- or 6-membered heteroarylindependently is mono-, or di-substituted wherein the substituentsindependently are selected from C₁₋₄-alkyl, and C₁₋₃-fluoroalkyl; or apharmaceutically acceptable salt thereof.
 8. A compound according toclaim 1; wherein the fragment -L-Ar² represents:

or a pharmaceutically acceptable salt thereof.
 9. A compound accordingto claim 1; wherein n represents the integer 1; or a pharmaceuticallyacceptable salt thereof.
 10. A compound according to claim 1 whereinsaid compound is:(2R,3R,4S,5R,6R)—N-benzyl-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-ethynylbenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-phenethyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(4-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(2-chlorobenzyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((3-chloropyridin-4-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((4-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-(trifluoromethyl)benzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(2-chlorobenzyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((3-(trifluoromethyl)pyridin-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((2-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((2-amino-4-chlorothiazol-5-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(isoxazol-4-ylmethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((5-chlorofuran-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(isothiazol-4-ylmethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((2-bromothiazol-4-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((2-morpholinothiazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((5-chlorothiophen-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((5-chlorothiazol-2-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-pyrazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((3-(trifluoromethyl)pyridin-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((4-(trifluoromethyl)pyrimidin-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((4,6-dimethoxypyrimidin-5-yl)methyl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((4-methylpyrimidin-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((5-methyl-1H-imidazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((4-chloroisothiazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-pyrazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((3-methylthiophen-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-pyrrol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((3-chlorothiophen-2-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((4-methylthiazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((2-methylthiophen-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-methoxybenzyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(2,6-dimethoxybenzyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-methyl-1H-imidazol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)—N-((1-ethyl-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-((1-isopropyl-1H-pyrazol-5-yl)methyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((1-(cyclopropylmethyl)-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-((1-methyl-1H-indol-2-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)-4-(4-(4-choro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)((1-methyl-1H-pyrazol-5-yl)methyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)—N-(3-chlorobenzyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)—N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)—N-((6-fluoro-3-methoxyquinoxalin-5-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-((3-chloroquinolin-2-yl)methyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-(((1S,2S)-2-hydroxycyclohexyl)(2-(trifluoromethyl)benzyl)carbamoyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-ylacetate;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-N-((1S,2S)-2-hydroxycyclohexyl-6-(hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(5-fluoro-2-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyano-5-methylphenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyano-5-methoxyphenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-methylphenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chlorophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyanophenyl)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(methoxy-d3)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(5-chloro-2-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-4-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-4-(trifluoromethyl)phenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-4-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-methylbenzo[d]triazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-(trifluoromethyl)phenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dibromophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,4-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-4-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-phenyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-methoxyphenyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(benzo[b]thiophen-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(5-chloro-2-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(2,5-dimethylbenzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(2-chlorobenzo[d]thiazol-6-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(5-bromo-2-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(4-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(3-(trifluoromethyl)phenyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-fluoro-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-fluoro-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(m-tolyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(2-methyl-1H-benzo[d]imidazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-6-)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-fluorophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromophenyl)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3-bromo-5-fluorophenyl-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-5-yl)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-fluorophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyano-5-fluorophenyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-brmo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(benzo[d]thiazol-6-yl)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3,4-dichloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;2-(((2R,3R,4S,5R,6R)-2-((3-chloro-5-cyanophenyl)((1S,2S)-2-hydroxycyclohexyl)carbamoyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)aceticacid;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(4,5-difluoro-2-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-broNo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-fluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3-fluoro-4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,4-difluoro-5-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyano-5-fluorophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-cyano-5-methoxyphenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(3-fluoro-5-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(2-methylbenzo[d]thiazol-6-yl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(4-fluoronaphthalen-1-yl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-chlorothiazol-2-yl)-1H-1,2,3-triazol-1-yl)-N-(2,3-difluorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(pyridin-2-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(naphthalen-2-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-N-(naphthalen-1-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(1,5-dimethyl-1H-pyrazol-3-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-bromo-5-cyanophenyl)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chloro-5-cyanophenyl)-4-(4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-chloro-5-cyanophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methoxyphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)-4-(4-(4-cyano-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-N-(3-cyano-5-methylphenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3-chlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycycloheptyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycycloheptyl)-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-((S)-3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-((R)-3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-(2-(4-hydroxypiperidin-1-yl)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-3-(2-(3-hydroxyazetidin-1-yl)-2-oxoethoxy)-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;2-(((2R,3R,4S,5R,6R)-2-((3,5-dichlorophenyl)((1S,2S)-2-hydroxycyclohexyl)carbamoyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)aceticacid;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide;(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-morpholinophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;or(2R,3R,4S,5R,6R)—N-(3,5-dichlorophenyl)-4-(4-(3,5-difluoro-4-((3-hydroxypropyl)amino)phenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-N-((1S,2S)-2-hydroxycyclohexyl)-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-carboxamide;or a pharmaceutically acceptable salt thereof.
 11. A pharmaceuticalcomposition comprising a compound according to claim 1, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier. 12-14. (canceled)
 15. A method for the prophylaxisor treatment of fibrosis of organs; liver diseases and disorders;cardiovascular diseases and disorders; cell proliferative diseases andcancers; inflammatory and autoimmune diseases and disorders;gastrointestinal tract diseases and disorders; urinary tract diseasesand disorders: pancreatic diseases and disorders; abnormalangiogenesis-associated diseases and disorders; brain-associateddiseases and disorders; neuropathic pain and peripheral neuropathy;ocular diseases and disorders; acute kidney injury and chronic kidneydisease; interstitial lung diseases and disorders; or transplantrejection; comprising administering to a subject in a need thereof aneffective amount of a compound according to claim 1, or of apharmaceutically acceptable salt thereof.
 16. A compound according toclaim 2; wherein at least one of said substituents is attached inpara-position of said phenyl and the substituent is selected fromhalogen, methyl, cyano, and methoxy; or a pharmaceutically acceptablesalt thereof.
 17. A compound according to claim 2; wherein at least oneof said substituents is attached in a meta-position of said phenyl andthe substituent is halogen; or a pharmaceutically acceptable saltthereof.
 18. A pharmaceutical composition comprising a compoundaccording to claim 10, or a pharmaceutically acceptable salt thereof,and a pharmaceutically acceptable carrier.
 19. A method for theprophylaxis or treatment of fibrosis of organs; liver diseases anddisorders; cardiovascular diseases and disorders; cell proliferativediseases and cancers; inflammatory and autoimmune diseases anddisorders; gastrointestinal tract diseases and disorders; urinary tractdiseases and disorders; pancreatic diseases and disorders; abnormalangiogenesis-associated diseases and disorders; brain-associateddiseases and disorders; neuropathic pain and peripheral neuropathy;ocular diseases and disorders; acute kidney injury and chronic kidneydisease; interstitial lung diseases and disorders; or transplantrejection; comprising administering to a subject in a need thereof aneffective amount of a compound according to claim 10, or of apharmaceutically acceptable salt thereof.